New York, New York and New Orleans, Louisiana--(Newsfile Corp. - June 15, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors with substantial losses that they have until August 10, 2026 to file lead plaintiff applications in a securities class action lawsuit against Zillow Group, Inc. (NASDAQ: ZG) (NASDAQ: Z) ("Zillow" or the "Company"), if they purchased or otherwise acquired Zillow Class A or Class C common stock between February 11, 2025 and May 7, 2026, inclusive (the "Class Period"). This action is pending in the United States District Court for the Western District of Washington.
Cannot view this video? Visit:
https://www.youtube.com/watch?v=hIyQUNEoCGc
What You May Do
If you purchased shares of Zillow as described above and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nasdaqgs-zg-z/?prs=nf to learn more. If you wish to serve as a lead plaintiff in this class action, you must petition the Court by August 10, 2026.
CLICK HERE for more information
About the Lawsuit
Zillow and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
The alleged false and misleading statements and omissions include, but are not limited to, that: (i) Zillow's agreement with Redfin was not a "partnership," but rather an acquisition of Redfin's business; (ii) as a result of the Redfin Agreement, Zillow faced a materially heightened risk of regulatory scrutiny and liability under federal antitrust laws; (iii) upon the filing of an antitrust lawsuit, Zillow continued to downplay its legal exposure; and (iv) as a result, Defendants' statements about Zillow's business, operations, and prospects, were materially false and misleading and or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
The case is Breidert v. Zillow Group, Inc., et al., 26-cv-02016.
To Learn More, Click HERE
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors, in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.
TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services
To learn more about KSF, you may visit www.ksfcounsel.com.
Honeywell International's (HON +3.12%) stock rose by 4.4% at 12:30 pm today on the news that its board of directors had formally approved the spinoff of Honeywell Aerospace.
Why Honeywell's breakup matters This is the final stage in the company's breakup, and will create a focused aerospace and defense company, Honeywell Aerospace, with the legacy Honeywell International company remaining as Honeywell Technologies, a focused building, process, and industrial automation company. The split matters because it creates two more focused companies, each with its own risk profile, capital requirements, and industry cycles. For reference, Honeywell also recently had an initial public offering (IPO) for its quantum computing business, Quantinuum.
Today's Change
(
3.12
%) $
6.87
Current Price
$
227.18
Honeywell Aerospace Both companies are well placed to do well. Honeywell Aerospace's electronics, controls, and power systems make it a leading player in the commercial aerospace and defense markets, and it's a beneficiary of a resurgent growth in commercial travel and a global ramp-up in defense spending driven by geopolitical conflict. Management recently held an investor day and called for compound annual sales growth of 6%-8% through 2030, with earnings growth above sales growth and cash flow above earnings growth.
Image source: Getty Images.
Honeywell Technologies The automation company also has an exciting future. Its process automation solution benefits from increased spending on energy security and decarbonization. Building automation has strong underlying growth drivers, stemming from regulatory requirements that push building owners to invest in smart buildings to reduce emissions. Finally, industrial automation end demand is driven by the need to reshore manufacturing and compete with low-labor-cost countries by automating production.
Management also held an investor day recently and called for 4%-6% annual growth over the next three years, accompanied by more than 10% annual adjusted earnings per share (EPS).Both companies are set for solid growth prospects, which could accelerate as management works to add value as stand-alone companies.
Lee Samaha has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Honeywell International. The Motley Fool has a disclosure policy.
SpaceX (SPCX +19.79%), the aerospace and AI company founded by Elon Musk, went public on June 12 at a valuation of $1.77 trillion, making it the largest IPO in history. Today, its market cap reached $2.40 trillion, making it the sixth-most-valuable company in the world.
That puts it ahead of tech giants like Broadcom, Meta, and Tesla, but could it overtake Amazon (AMZN +3.13%) -- which is worth $2.65 trillion -- within the next few days?
Image source: Getty Images.
Can SpaceX maintain its sky-high valuation? SpaceX's revenue rose 33% to $18.67 billion in 2025. That growth rate is impressive, but the company's market cap of $2.40 trillion values it at 128 times that figure. That sky-high price-to-sales ratio makes SpaceX seem more like a meme stock than a growth stock.
SpaceX is also unprofitable. After recasting its results to include its integration of xAI (which owns X and Grok) this year, it posted a net loss of $4.94 billion in 2025. The losses from that new AI division and its space division are completely offsetting Starlink's profits.
SpaceX also plans to ramp up its AI investments, so its bottom line should stay in the red for the foreseeable future. Therefore, investors shouldn't be surprised if SpaceX sells more shares (since it offered less than 5% of its shares in its IPO) and takes on more debt.
Even if SpaceX grows its revenue at a 30% CAGR from 2025 to 2028, it would still look overvalued at 58 times its $41 billion in revenue for the final year.
Rocket Lab (RKLB +6.72%), which competes with SpaceX in the orbital rocket market, trades at 37 times its 2028 sales. AST SpaceMobile (ASTS +6.26%), which competes with SpaceX in the satellite internet services market, trades at just 13 times its 2028 sales. Rocket Lab and AST SpaceMobile are both smaller than SpaceX, but they're growing much faster. In other words, SpaceX's stock could lose half its value before it's fairly valued relative to its industry peers.
Today's Change
(
3.13
%) $
7.46
Current Price
$
246.01
Over the next few days, a fear of missing out might boost SpaceX's market cap past Amazon's and make it the world's fifth-most-valuable company. But those gains won't be sustainable because it's much pricier than Amazon.
Amazon, the world's largest e-commerce and cloud infrastructure company, is only valued at three times this year's sales and 28 times this year's earnings. Analysts expect its revenue and EPS to grow at CAGRs of 14% and 21%, respectively.
Amazon's e-commerce business will continue to grow as it upgrades its logistics network and enters more overseas markets. Its cloud infrastructure business, which already hosts the world's top generative AI platforms, will profit from the ongoing AI boom.
Most of Amazon's revenue comes from its e-commerce business, but most of its profits come from its cloud business. That's why it can consistently expand its e-commerce ecosystem with discounts, low-margin hardware devices, and more perks for its Prime subscribers. It also continues to expand its high-margin advertising business, which is evolving into its second profit engine alongside its cloud business by peddling more promoted listings and integrated ads.
That's why Amazon is firmly profitable, while SpaceX isn't. If Amazon matches analysts' estimates and maintains its forward multiple, its stock would rise by 42% to $350 over the next 12 months, boosting its market cap to $3.76 trillion. By then, I'd expect SpaceX's valuation to settle down to more reasonable levels -- so it will likely be much less valuable than Amazon.
Investors shouldn't expect SpaceX's stock to keep rising SpaceX has been defying gravity since its market debut, but that euphoria won't last very long. Its initial rally is attracting a lot of attention, but that momentum will fade once its IPO investors flip their shares and its short-term traders take the money and run. Instead of chasing its post-IPO rally, investors should ignore the noise and wait for its inevitable pullback.
Leo Sun has positions in Amazon and Meta Platforms. The Motley Fool has positions in and recommends AST SpaceMobile, Amazon, Broadcom, Meta Platforms, Rocket Lab, and Tesla. The Motley Fool has a disclosure policy.
WINONA, Minn.--(BUSINESS WIRE)--Fastenal Company (NASDAQ: FAST) has been named as an official partner of the 2026 Special Olympics USA Games ('USA Games'), to be held June 20–26 in Minnesota's Twin Cities area. With the support of partners like Fastenal, the USA Games will bring together thousands of athletes, coaches, fans, and volunteers from across the country in a national celebration of the human spirit.
Through the partnership, Fastenal has donated over $100,000 worth of products to help the USA Games team execute one of the largest humanitarian/sports events Minnesota has held in 35 years. The donation includes tools and equipment to build out and maintain dozens of venues, as well as sports-focused items like rolling storage systems to quickly move athletic medical supplies where they're needed.
It also includes a variety of safety gear to protect workers, including Fastenal's own Body Guard® brand. As a value-added service, Fastenal used their Custom Logo service to print the Special Olympics logo on nearly 500 donated safety vests and hardhats – a solution to help identify staff and volunteers and reduce product loss.
"Fastenal has been a phenomenal partner," said Kevin Quiring, chief development officer for the USA Games. "They've had a patient, consultative approach as our specifications evolved, and all the items have arrived on schedule. Bottom line: Fastenal truly understands the importance of a successful USA Games to our athletes and the Special Olympics mission."
"Fastenal's support reflects their alignment with our vision for a more inclusive future," added Christy Sovereign, CEO of the USA Games. "We're excited to work together to showcase the power of human potential and inspire communities across the country."
There's a long history behind this commitment. For decades, several of Fastenal's distribution and service centers have partnered with community rehabilitation providers to offer meaningful employment for people with mental and physical disabilities. In 2025, Fastenal was named Partner of the Year by Winona ORC Industries, a Winona, Minnesota community leader in providing training and job opportunities to people with disabilities.
"Fastenal is founded on a core belief in people – that with the right training, support, and opportunity, we all have the ability to do amazing things," said Sally Olson, director of marketing for Fastenal who oversees community involvement. "We're proud to be a partner of the USA Games because it's about helping athletes of all abilities realize their true potential."
About Fastenal
Organizations around the world rely on Fastenal to help them simplify and secure the supply chain for a broad range of industrial products. To understand our customers' challenges and provide services and solutions that fit their unique needs, we've built out the most extensive presence in our industry, with a vast network of local teams and embedded technology. At the heart of it all is a simple commitment: great people, close to the customer, backed by world-class logistics, technology, and resources.
Additional information regarding Fastenal is available on our website at www.fastenal.com.
About 2026 Special Olympics USA Games
The 2026 Special Olympics USA Games—scheduled for June 20-26, 2026, across Minnesota's Twin Cities with sports competitions at the University of Minnesota and the National Sports Center in Blaine—is a national celebration of inclusivity, changing perceptions and the ability of the human spirit rising above limitations. The USA Games, with co-presenting partners Jersey Mike's Subs and UnitedHealthcare, will be one of the biggest U.S. sporting events of the year, drawing tens of thousands of fans to celebrate the ability of nearly 3,000 incredible athletes from all 50 states as they compete in 16 Olympic-type team and individual sports. As a state with a long history of championing diversity, equity and inclusion, the USA Games now bring an unrivaled opportunity for Minnesotans to spark new energy around the Special Olympics movement and create a lasting legacy of positive change.
After a rough start to 2026, CVS Health (CVS 1.25%) shares have more than made up for their initial losses, surging in recent months on the heels of promising Medicare-related developments. Shares are already up over 25% year to date.
But even as shares keep climbing toward the top of sell-side analyst price targets, including the most recently raised price target, don't assume the runway is limited to this figure. Given CVS's strong comeback and potential rerating, it could remain one of the best-performing blue chip stocks this year.
Image source: Getty Images
The latest price target raise for CVS Health On June 8, Mizuho analyst Ann Hynes, while reiterating her bullish rating on CVS Health, raised her price target by 4.5%, from $110 to $115 per share. With shares trading around $97 at the time, this represented about 18.5% upside, but CVS Health's subsequent rally has narrowed that to about 13%.
Today's Change
(
-1.25
%) $
-1.28
Current Price
$
100.68
Following the stock's latest rally, investor sentiment has shifted strongly. Investors are likely no longer anticipating just "better than expected" results. There may now be an increasing pool of investors who believe that the company can continue to beat expectations. I believe this view is more than reasonable, with the potential for shares to reach levels above Mizuho's aforementioned target.
Loftier price levels within reach Currently, CVS Health trades for just under 13.8 times forward earnings. If the stock were to rise to $115 per share, based on forecasts calling for 2026 earnings of $7.43 per share, CVS Health would be trading at a forward multiple of around 15.5.
The market now fully understands that CVS is a diversified healthcare services company today, similar to UnitedHealth Group. With UnitedHealth now rerated to a forward valuation in the low 20s, such a valuation may be reasonable for CVS as well, especially as forecasts call for further double-digit earnings growth in 2027. If this stock were to rise to a forward multiple in the high teens, or even up to 20 times forward earnings, it could hit prices near $150 per share.
Thomas Niel has positions in UnitedHealth Group. The Motley Fool recommends CVS Health and UnitedHealth Group. The Motley Fool has a disclosure policy.
SAN FRANCISCO, June 15, 2026 (GLOBE NEWSWIRE) -- Roblox Corporation (NYSE: RBLX) faces a securities class action lawsuit after its April 30, 2026 Q1 2026 report indicating a surprisingly large sequential decline in daily active users (“DAUs”) tempered by its age-check rollout. The news drove the price of Roblox shares down $10.13 (-18%) the next trading day and erased over $6.7 billion from the company’s market capitalization.
The lawsuit seeks to represent investors who purchased or otherwise acquired Roblox common stock between October 30, 2025 and April 30, 2026.
National shareholder rights firm Hagens Berman is investigating the legal claims that Roblox and its co-defendants violated the federal securities laws. The firm encourages Roblox investors who suffered substantial losses to submit your losses now.
Class Period: Oct. 30, 2025 – Apr. 30, 2026
Lead Plaintiff Deadline: Aug. 7, 2026
Visit: www.hbsslaw.com/investor-fraud/rblx
Contact the Firm Now: [email protected]
844-916-0895
Roblox Corporation (RBLX) Securities Class Action:
The primary focus of the litigation is on the propriety of Roblox’s disclosures about the impact on its business and prospects of the age-check verification rollout aimed at increasing safety within certain social features on its platform. The rollout began in November 2025.
Throughout the Class Period, Roblox has characterized its rollout as the “gold standard” intended to be implemented with “no friction.” The company has also touted its high year-over-year DAU growth and related revenue and bookings growth.
As recently as February 5, 2026, during Roblox’s Q4 2025 earnings call, CEO David Baszucki responded to an analyst’s question about additional detail about the age-check rollout, assuring investors that “[w]e’re very excited and proud of the way our age verification rollout has gone” and “we found so many other opportunities for optimization that I’m very pleased and happy about the way the rollout has gone.”
The complaint alleges that Roblox made false and misleading statements while failing to disclose important information to investors about the true state of the company’s growth potential. More specifically, the complaint alleges that Roblox would see significant growth slowdown as enrollments in its age-check rollout would quickly taper, compounding the resulting slowdown in on-line platform communication and resulting in app store rating reductions and a swift reduction in organic growth.
The truth entered the market on April 30, 2026. That day, Roblox reported its Q1 2026 financial results, revealed a steep deceleration in year-over-year and sequential DAU growth, slashed its 2026 revenue guidance (reflecting ongoing shrinkage in DAU growth), and severely cut its 2026 bookings growth midpoint from 24% to just 10%.
The company blamed its adverse situation on just 51% of Roblox global DAUs having age checked and further revealed that “as a result of age check […] we have seen a reduction in app store ratings, and we believe this may be contributing to a reduction in organic sign-ups that typically flow from app stores.” Roblox also said its lowered prospects are the result of “continued friction” resulting from the age-check rollout.
“We’re focused on when Roblox and its management knew of the adverse consequences of the age-check rollout and whether they intentionally misled investors it,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.
If you invested in Roblox and have substantial losses, or have knowledge that will assist the firm’s investigation, submit your losses now.
If you’d like more information and answers to other frequently asked questions about the Roblox case and the firm’s investigation, read more.
Whistleblowers: Persons with non-public information regarding Roblox should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected] .
About Hagens Berman
Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
Benchmark Says Strategy Has Several Buffers Before Bitcoin Sales Become NecessaryBenchmark analyst Mark Palmer called the death spiral narrative a story that skips several steps.
Strategy’s $1 billion cash reserve must be depleted before any meaningful Bitcoin sales enter the conversation, and the perpetual preferred stock (NASDAQ:STRC) carries no hard maturity date that would trigger accelerated selling.
“The death-spiral story assumes that Strategy is one bad week from selling Bitcoin, and it skips several steps to get there,” Palmer wrote.
“The company would have to move through a long sequence of failures before its Bitcoin reserve, currently valued at almost $55 billion, would even enter the conversation,” he added.
Moreover, Strategy sold 32 Bitcoin for $2.5 million between May 26 and May 31 to fund STRC dividend distributions, its first sale since December 2022.
The company followed that with a 1,587 Bitcoin purchase for $100 million last week at an average price of $63,024, bringing total holdings to 846,842 BTC.
TD Cowen Says STRC Has Preserved Capital Even During Sharp Bitcoin DrawdownsTD Cowen analysts Lance Vitanza and Jonnathan Navarrete added that STRC dividend obligations remain manageable given current reserves, arguing the preferred stock has actually proven its value during volatility.
“STRC has materially dampened volatility across drawdowns, offering positive or near-flat returns even during periods when BTC experienced significant declines,” TD Cowen wrote.
“This dynamic supports the positioning of STRC as a capital preservation and income vehicle, in contrast to BTC’s high-volatility growth profile.” Both firms carry a Buy rating on MSTR.
MSTR Clears First Fibonacci Level With $144 to $148 Cluster As The Real TestMSTR cleared the 0.236 Fibonacci level at $132.51 Monday, the first meaningful structural reclaim since May’s $195 peak.
The Fibonacci recovery ladder is now clearly mapped with the full bearish EMA stack overhead.
The 0.382 Fib at $144.50 coincides almost exactly with the 50 EMA at $148.79 and Supertrend at $148.04, making that cluster the make-or-break zone for this recovery.
Closing above $144.50 targets $154.19 then $163.88. Losing $132.51 fades the momentum and retests the June lows at $113.
Image: Shutterstock
Market News and Data brought to you by Benzinga APIs
Strategy stock is among today’s top performers. Why is MSTR stock surging? Bitcoin Jumps On Iran DealBitcoin jumped to its strongest level in almost two weeks after the US and Iran announced a deal to end hostilities and reopen the Strait of Hormuz, according to Bloomberg.
The interim peace deal sparked a broad return of risk appetite, sending global equities higher and pushing oil prices lower. By mid‑afternoon in New York, the S&P 500 was pacing toward its strongest single‑day gain since April.
Capital.com’s Daniela Hathorn said the Iran deal is a key test for crypto, which has behaved like a high‑beta risk trade during the conflict amid ETF outflows and soft sentiment. She argued that a durable agreement would lift a major macro overhang and may bolster risk appetite, especially if it helps drive oil lower and cool inflation worries.
MSTR Stock: Key Technical Levels To WatchStrategy is still working through a corrective phase. Even after Monday's bounce, the stock trades 7.5% below its 20‑day simple moving average at $144.50 and 13.6% below its 50‑day at $154.79, keeping the intermediate trend pointed lower. The bigger overhang remains the 200‑day simple moving average at $196.21, with price still 31.9% beneath that long‑term trend line.
Momentum remains soft. MACD sits below its signal line and the histogram is negative, a setup that typically means rallies are more likely to fade unless buyers can build sustained pressure. When MACD is below the signal line, upside moves tend to be fragile until momentum turns.
The chart also has clear structural markers. Strategy broke support in June and set a swing low that same month, so bulls want to see higher lows form above that zone to argue the downtrend is easing. The death cross from October 2025, when the 50‑day slipped under the 200‑day, reinforces that rallies can meet supply until price starts reclaiming major moving averages.
Key Resistance: $149.50 — a nearby rebound ceiling that lines up with the area just under the 50-day moving average zone where rallies can stall Key Support: $118.50 — a nearby floor tied to a recent pivot area above the 52-week low zone ($104.17) MSTR Shares Are Trending HigherMSTR Price Action: Strategy shares were up 7.23% at $132.93 at the time of publication on Monday, according to Benzinga Pro.
Image: Shutterstock
Market News and Data brought to you by Benzinga APIs
Strategy Inc (NASDAQ:MSTR) experienced a significant Power Inflow alert, a key bullish indicator that is closely tracked by traders who value order flow analytics, specifically institutional and retail order flow data.
Understanding the Power Inflow Signal
Order flow analytics analyze real-time buying and selling trends by examining the volume, timing, and order size across both retail and institutional traders. These insights offer a more detailed understanding of price behavior and market sentiment for a stock, allowing the trader or institution to make the most informed decision possible.
MSTR Intraday Performance
At the time of the Power Inflow, MSTR was priced at $131.47. Following the signal:
• Intraday High As Of 2:00PM EST: $135.53 (+3.09%)
This article is for informational purposes only and does not constitute financial advice, investment recommendations, or a solicitation to buy or sell securities. The analysis is based on stock order flow data, but accuracy is not guaranteed. Investing involves risk, including possible loss of principal, and past performance is not indicative of future results. Please consult a licensed financial advisor before making any investment decisions.
Benzinga Disclaimer: This article is from an unpaid external contributor. It does not represent Benzinga’s reporting and has not been edited for content or accuracy.
Market News and Data brought to you by Benzinga APIs
Small-cap stocks should be a part of just about any well-balanced investment portfolio. Two to consider are State Street SPDR S&P 600 Small Cap Value ETF (SLYV 0.53%), which offers higher recent returns and a slight yield edge, and the Vanguard Small-Cap Value ETF (VBR 0.09%), which provides a lower expense ratio and broader diversification.
Small-cap value stocks offer a way to capture the size and value premiums historically observed in equity markets. This comparison examines whether the State Street fund’s concentrated, index-driven approach or the Vanguard fund’s ultra-low-cost, highly diversified portfolio better fits a long-term investment strategy.
Snapshot (cost & size)MetricSLYVVBRIssuerSPDRVanguardExpense ratio0.15%0.05%1-yr return (as of June 12, 2026)39.10%27.95%Dividend yield1.80%1.70%Beta0.980.95AUM$4.8 billion$65.5 billionBeta measures price volatility relative to the S&P 500; beta is calculated from five-year monthly returns. The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield as of the closing prices of the funds on June 12, 2026.
The Vanguard fund is the more affordable option, charging a 0.05% expense ratio compared to 0.15% for the State Street fund. While SLYV offers a slightly higher distribution yield, the difference between the two payouts remains marginal for most income-focused investors.
Performance & risk comparisonMetricSLYVVBRMax drawdown (5 yr)(28.70%)(24.20%)Growth of $1,000 over 5 years (total return)$1,356$1,494What's insideVanguard Small-Cap Value ETF holds 838 stocks, with Financial Services (18%), Industrials (17.9%), and Consumer Cyclical (12.5%) as its top sectors. Its largest positions include Flex (FLEX 0.33%) at 0.76%, Jabil (JBL +0.21%) at 0.77%, and NRG Energy (NRG +3.93%) at 0.75%. Launched in 2004, the fund has paid $4.14 per share over the trailing 12 months and manages $65.5 billion in assets under management (AUM).
In contrast, State Street SPDR S&P 600 Small Cap Value ETF tracks the S&P SmallCap 600 Value Index with 458 holdings. Its top sectors are Financial Services (19.5%), Consumer Cyclical (15.4%), and Technology (13.4%). Leading positions include Molina Healthcare (MOH +0.79%) at 1.04%, Enphase Energy (ENPH 4.02%) at 1.04%, and Eastman Chemical (EMN +1.21%) at 1.01%. Launched in 2000, it has a trailing-12-month dividend of $1.90 per share and $4.8 billion in AUM.
The State Street SPDR S&P 600 Small Cap Value ETF has had a great recent 12 months, returning more than 39% to investors, besting the small-cap category by three percentage points. The Vanguard Small-Cap Value ETF has left a fair bit of returns on the table, relative to the category, with 28% returns over the past 12 months.
Yet small caps can and often do go out of favor in the market for long periods of time. Over the long-run Vanguard’s fund beats the State Street offering. Over the past three years, VBR has returned 16.5%, compared to 14.8% for SPLV and a category return of 15.3%. Over five years, VBR wins again, with returns of 7.8% to SLYV’s 6.5%. Over 10 years through March 31, the Vanguard fund posted a 10.1% return compared to 9.4% for the State Street contender.
In short, both funds offer strong performance and excellent exposure to the small-cap stock category. Given the historical trend of small caps to go out of favor for longer periods of time, the lower-cost Vanguard Small-Cap Value ETF is the choice here.
For more guidance on ETF investing, check out the full guide at this link.
Eutelsat (ISIN: FR0010221234 – Euronext Paris / London Stock Exchange: ETL) today announced the signature, through the French Directorate General of Armaments (DGA), of the CENTAURE contract, marking the first call-off contract under the €1bn NEXUS framework agreement with the French Ministry of the Armed Forces and Veterans inked in June 2025.
This new milestone marks the first concrete implementation of the NEXUS project (Neo-Space for Multiple Secure Uses), a strategic initiative led by the French Ministry of the Armed Forces and Veterans to strengthen France's military satellite communications capabilities by combining sovereign assets with trusted commercial capacity. Against a geopolitical backdrop characterised by growing demand for secure, resilient and sovereign connectivity, France is continuing to enhance its space capabilities while preparing for the deployment of the future European IRIS2 constellation.
The total CENTAURE contract is valued at circa €350 million1, for a duration of up to eight years. It is comprised of an initial firm commitment of €138 million2 over a period of four years for the provision of low Earth orbit (LEO) satellite capacity across multiple areas of strategic interest to the French Armed Forces as well as an initial stage aimed at enhancing the security of Eutelsat's OneWeb services.
This approach ensures the French Armed Forces benefit from sustained access to low-latency, globally available satellite resources, while maintaining operational continuity and flexibility during the ramp-up of the European IRIS2 programme.
Through its OneWeb constellation, the only global LEO constellation currently operated by a European provider and readily available for governmental use, Eutelsat delivers secure operational capabilities tailored to the requirements of today's most demanding defence missions.
The NEXUS agreement demonstrates how trusted European commercial space infrastructure can complement sovereign defence assets and accelerate the deployment of next-generation capabilities. As space becomes an increasingly critical component of national security, Europe must be able to rely on resilient, secure and sovereign connectivity solutions under its own control.
Jean‑François Fallacher, Chief Executive Officer of Eutelsat, said: "The signature of the CENTAURE contract marks a major milestone in the implementation of the NEXUS framework agreement and reflects the continued trust placed by the French Ministry of the Armed Forces in the capabilities of our OneWeb constellation. In a profoundly transformed strategic environment, secure, resilient and low-latency connectivity has become a decisive driver of military operational effectiveness. With an infrastructure that is immediately available and field-proven, Eutelsat is now delivering a concrete response to the needs of the French Armed Forces.”
Patrick Pailloux, Director General for Armaments (DGA) added: "With the CENTAURE call-off contract, France is taking another step forward in the modernisation of its military satellite communications capabilities. Recent conflicts have demonstrated the critical importance of diverse, secure, resilient and sovereign connectivity for the conduct of modern operations. By relying on a trusted European solution that is immediately available and provides global low-latency coverage, the French Ministry of the Armed Forces and Veterans is acquiring the necessary resources to address today’s operational challenges while laying the groundwork for the future sovereign European capabilities that will be delivered through the IRIS2 programme."
About Eutelsat Communications
Eutelsat is a global leader in satellite communications, delivering connectivity and broadcast services worldwide. Eutelsat was formed through the combination of the Company and OneWeb in 2023, becoming the first fully integrated GEO-LEO satellite operator with a fleet of 31 Geostationary (GEO) satellites and a Low Earth Orbit (LEO) constellation of more than 600 satellites. Eutelsat addresses the needs of customers in four key verticals of Video, where it distributes around 6,300 television channels, and the high-growth connectivity markets of Mobile Connectivity, Fixed Connectivity, and Government Services. Eutelsat's unique suite of in-orbit assets and ground infrastructure enables it to deliver integrated solutions to meet the needs of global customers. The Company is headquartered in Paris and Eutelsat employs more than 1,600 people across more than 75 countries. Eutelsat is committed to delivering safe, resilient, and environmentally sustainable connectivity to help bridge the digital divide. The Company is listed on the Euronext Paris Stock Exchange (ticker: ETL) and the London Stock Exchange (ticker: ETL).
Disclaimer
The forward-looking statements included herein are for illustrative purposes only and are based on management’s views and assumptions as of the date of this document. Such forward-looking statements involve known and unknown risks. For illustrative purposes only, such risks include but are not limited to: risks related to the health crisis; operational risks related to satellite failures or impaired satellite performance, or failure to roll out the deployment plan as planned and within the expected timeframe; risks related to the trend in the satellite telecommunications market resulting from increased competition or technological changes affecting the market; risks related to the international dimension of the Group's customers and activities; risks related to the adoption of international rules on frequency coordination and financial risks related, inter alia, to the financial guarantee granted to the Intergovernmental Organization's closed pension fund, and foreign exchange risk. Eutelsat Communications expressly disclaims any obligation or undertaking to update or revise any projections, forecasts or estimates contained in this document to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The information contained in this document is not based on historical facts and should not be construed as a guarantee that the facts or data mentioned will occur. This information is based on data, assumptions and estimates that the Group considers as reasonable.
1
Circa €300m net of value added tax (VAT)
2
Circa €115m net of value added tax (VAT)
View source version on businesswire.com: https://www.businesswire.com/news/home/20260615949467/en/
Lucid Group stock is moving in positive territory. Why is LCID stock advancing? What Is Driving Lucid Group’s Stock Today?Monday’s upward momentum is being driven by a macroeconomic breakthrough. Following a peace agreement between the United States and Iran that reopened the Strait of Hormuz, crude oil prices plummeted roughly 5%. This sharp collapse in energy costs immediately eased persistent inflation fears, causing Treasury yields to retreat across the board, with the 10-year yield dropping to 4.48%.
For a high-growth, capital-intensive tech company like Lucid, lower inflation and falling yields are highly favorable indicators. They reduce the broader pressure of high borrowing costs and improve the present valuation of future cash flows.
This macro relief sparked a massive “risk-on” rotation, driving the tech-heavy Nasdaq-100 up over 3%. As investors flooded back into growth and clean energy sectors, Lucid benefited from the rising tide.
Critical Price Levels for LCID to WatchEven with Monday's bounce, the longer-term chart remains heavy: LCID is down 75.19% over the past 12 months and is still trading 6.9% below its 20-day SMA, 19.2% below its 50-day SMA, and 57.1% below its 200-day SMA. That "stack" of moving averages overhead keeps rallies vulnerable to selling into resistance.
Trend structure is still bearish, with the 20-day SMA below the 50-day SMA and the 50-day SMA below the 200-day SMA, signaling the stock hasn't repaired its longer-cycle damage yet. The most actionable near-term test is whether price can reclaim the 20-day area and then hold above it long enough to start flattening the short-term averages.
For momentum, MACD is below its signal line and the histogram is negative, which points to upside pressure cooling versus the prior upswing. In plain terms, when MACD sits under its signal line, it often means buyers need a fresh push to keep a rebound going.
Key Resistance: $5.73 — the 20-day SMA is the nearest overhead trend line and a common "make-or-break" level for short-term rebounds Key Support: $4.47 — the 52-week low is the clearest downside reference if the recent bounce fails What Is Lucid Group’s Business Model?Lucid Group is a technology and automotive company focused on developing next-generation electric vehicle (EV) technologies, with a direct-to-consumer model that includes online sales plus a distributed retail and service footprint. A big part of the company's identity is in-house hardware and software work, vertical integration, and a clean-sheet engineering approach.
Its current flagship is the Lucid Air, positioned as a luxury sedan aimed at redefining the high-end EV segment. Geographically, the business spans North America, the Middle East, and other international markets, which means execution and demand can vary by region as EV adoption and competitive pressure shift.
LCID Stock Price Movement on MondayLCID Stock Price Activity: Lucid Group shares were up 1.54% at $5.28 at the time of publication on Monday, according to Benzinga Pro data.
Image: Shutterstock
Market News and Data brought to you by Benzinga APIs
NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- IMPORTANT DATE: July 28, 2026. Investors who purchased Lucid Group, Inc. (NASDAQ: LCID) securities between February 25, 2026 and April 13, 2026 and wish to seek appointment as lead plaintiff must file a motion by this date. Start your claim now before the deadline. You may also contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.
LCID shares lost $1.13 per share (11.35%) following the April 3, 2026 revelation of a 29-day Gravity SUV delivery halt, then declined an additional $0.44 per share (4.76%) on April 14, 2026 when preliminary Q1 revenue of $280 million to $284 million fell $150 million short of consensus expectations. A securities class action is now pending in the U.S. District Court for the Northern District of California.
What Is a Lead Plaintiff?
Under the Private Securities Litigation Reform Act of 1995, the lead plaintiff is the shareholder or group of shareholders appointed by the court to represent the interests of the entire class. In the LCID action, the lead plaintiff will direct litigation strategy, approve major decisions, and work with lead counsel to maximize recovery for all class members who purchased shares during the February 25 to April 13, 2026 Class Period.
Lead Plaintiff Facts
The court typically appoints the applicant with the largest financial interest in the relief soughtLead plaintiff applicants must demonstrate they purchased LCID securities during the Class Period and suffered lossesServing as lead plaintiff does not require any out-of-pocket payment or upfront costThe lead plaintiff is not personally liable for legal fees if the case is unsuccessfulLead plaintiffs receive the same per-share recovery as all other class members, plus reimbursement of reasonable costsMultiple investors may apply jointly as a lead plaintiff group Post-Deadline Procedures
After the July 28, 2026 deadline passes, the court will review all competing motions and select a lead plaintiff. This process typically takes 30 to 60 days. Once appointed, the lead plaintiff selects lead counsel, and the litigation proceeds through discovery, class certification, and ultimately trial or settlement.
Absent Class Member Rights
Investors who do not apply for lead plaintiff status are not excluded from the case. Absent class members retain full rights to participate in any recovery. No action is required before the deadline to preserve your ability to share in a future settlement or judgment. The deadline applies only to those seeking the lead plaintiff role.
Find out if you qualify to recover losses or contact Joseph E. Levi, Esq. at (212) 363-7500.
"The lead plaintiff process is designed to ensure the class is represented by shareholders with substantial interests. In the Lucid case, where alleged concealment of a supplier quality crisis preceded over $150 million in missed revenue expectations, investors with significant losses should evaluate whether lead plaintiff appointment serves their interests." -- Joseph E. Levi, Esq.
Levi & Korsinsky, LLP | Top 50 Securities Firm | (212) 363-7500 | www.zlk.com
Frequently Asked Questions About the LCID Lawsuit
Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.
Q: How do I know if I lost enough money to be the lead plaintiff? A: There is no minimum loss threshold. Courts appoint the investor with the largest provable loss who is willing and able to represent the class adequately. Contact Levi & Korsinsky before July 28, 2026 to evaluate.
Q: What do LCID investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [email protected] or (212) 363-7500. No immediate action is required to remain eligible as a class member.
Q: What if I already sold my LCID shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold them. Investors who bought during the class period and sold at a loss may still participate.
Q: What if I missed the lead plaintiff deadline? A: The deadline applies only to investors seeking lead plaintiff appointment. Class members who miss it can still participate in any settlement or recovery.
Q: What does it cost me to participate? A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.
DALLAS, June 15, 2026 (GLOBE NEWSWIRE) -- Dave & Buster's Entertainment, Inc. (NASDAQ: PLAY) (“Dave & Buster's” or “the Company”), an owner, operator, and franchisor of entertainment and dining venues, today announced financial results for its first quarter of fiscal 2026 ended May 5, 2026.
First Quarter 2026 Financial Summary
Revenue of $559.2 million decreased 1.5% from the first quarter of fiscal 2025.Comparable store sales decreased 5.4% compared to the same calendar period in fiscal 2025.Net income totaled $5.7 million, or $0.16 per diluted share, compared to net income of $21.7 million, or $0.62 per diluted share in the first quarter of fiscal 2025. Adjusted net income1 totaled $7.8 million, or $0.22 per diluted share, compared to Adjusted net income1 of $26.7 million, or $0.76 per diluted share in the first quarter of fiscal 2025.Adjusted EBITDA1 was $123.2 million compared to $136.1 million in the first quarter of fiscal 2025.Adjusted free cash flow2 was positive $25.3 million compared to negative $58.8 million in the first quarter of fiscal 2025. Additional Events and Commentary
The Company opened one new domestic store in the first quarter and has opened three additional domestic stores in the second quarter.The Company has completed remodels of six Dave & Buster’s stores thus far in fiscal 2026 and expects to complete two additional Dave & Buster’s store remodels during the remainder of fiscal 2026.The Company opened its fifth international franchise store in May and sixth international franchise store in June, and expects to open at least one additional international franchise store during the remainder of fiscal 2026. “While first quarter results fell short of expectations, our back-to-basics strategy is gaining clear traction,” said Tarun Lal, Chief Executive Officer. “We are driving meaningful progress across food and beverage, marketing, and our refreshed remodel program, which are delivering a sharper value proposition and driving a stronger guest experience. We have the right strategy, the right team, and the right momentum, and we are highly confident in our ability to drive positive comps for the remainder of the year while generating over $100 million in free cash flow in fiscal 2026.”
________________________________1Adjusted EBITDA and Adjusted net income are non-GAAP financial measures. Please see the discussion under Non-GAAP Measures and the reconciliations at the end of this release for additional information concerning these and other non-GAAP financial measures.2Adjusted free cash flow is a non-GAAP financial measure. Adjusted free cash flow equals Net Cash Provided by Operating Activities less Capital Expenditures plus Payments from landlords (sale leaseback transactions). Please see the Company’s Quarterly Report on Form 10-Q for additional information regarding these values.
Cash Flow and Liquidity
The Company generated $25.3 million in Adjusted free cash flow during the first quarter, ending the quarter with $499.1 million of available liquidity.1
Quarterly Report on Form 10-Q Available
The Company’s Quarterly Report on Form 10-Q, which will be available at www.sec.gov and on the Company’s investor relations website, contains a thorough review of its financial results for the first quarter ended May 5, 2026.
Investor Conference Call and Webcast
Management will host a conference call to discuss these results on Monday, June 15, 2026 at 4:00 p.m. Central Time (5:00 p.m. Eastern Time). Both the live and archived webcasts of the conference call will be available at ir.daveandbusters.com. Participants in the U.S. can access the conference call by dialing toll-free (888) 596-4144, and international participants can access by dialing +1 (646) 968-2525. The conference ID is 2926680. A replay will be available after the call beginning at 6:00 p.m. Central Time (7:00 p.m. Eastern Time) and can be accessed by dialing toll-free (800) 770-2030 or by the toll number +1 (609) 800-9909. The replay conference ID is also 2926680.
About Dave & Buster’s Entertainment, Inc.
Founded in 1982 and headquartered in Coppell, Texas, Dave & Buster's Entertainment, Inc. is the owner and operator of 247 stores in North America that offer premier entertainment and dining experiences to guests through two distinct brands: Dave & Buster’s and Main Event. The Company has 182 Dave & Buster’s branded stores in 43 states, Puerto Rico, and Canada and offers guests the opportunity to “Eat Drink Play and Watch” all in one location. Each store offers a full menu of entrées and appetizers, a complete selection of alcoholic and non-alcoholic beverages, and an extensive assortment of entertainment attractions centered around playing games and watching live sports and other televised events. The Company also operates 65 Main Event branded stores in 23 states across the country, and offers state-of-the-art bowling, laser tag, hundreds of arcade games and virtual reality, making it the perfect place for families to connect and make memories. Internationally, the Company is in early-stage growth as a franchisor of its brands with six Dave & Buster’s franchise stores currently open. For more information about each brand, visit daveandbusters.com and mainevent.com.
Forward-Looking Statements
The Company cautions that this release contains forward-looking statements. These forward-looking statements involve risks and uncertainties, including: our ability to continue as a going concern; our ability to obtain waivers, and thereafter continue to satisfy covenant requirements under our revolving credit facility; our ability to access other funding sources; our overall level of indebtedness; general business and economic conditions; the impact of competition; the seasonality of the Company's business; adverse weather conditions; future commodity prices; guest and employee complaints and litigation; fuel and utility costs; labor costs and availability; changes in consumer and corporate spending; changes in demographic trends; changes in governmental regulations; unfavorable publicity; our ability to open new stores; and acts of God. Accordingly, actual results may differ materially from the forward-looking statements, and the Company therefore cautions you against relying on such forward-looking statements. The Company intends these forward-looking statements to speak only as of the time of this release and does not undertake to update or revise them as more appropriate information becomes available, except as required by law.
________________________________1Available liquidity is defined as cash and cash equivalents plus availability under the Company’s $650.0 million revolving credit facility.
Non-GAAP Measures
To supplement its consolidated financial statements, which are prepared and presented in accordance with accounting principles generally accepted in the United States of America (“GAAP”), the Company uses the following non-GAAP financial measures: Adjusted EBITDA, Credit Adjusted EBITDA (calculated in accordance with the Company’s Credit Facility), Net Total Leverage Ratio (calculated in accordance with the Company’s Credit Facility), Store operating income before depreciation and amortization, Adjusted net income (loss), Adjusted net income (loss) per share - diluted, and Adjusted free cash flow reconciliations or numerical inputs of which can be found on the following pages or in the Company’s Quarterly Report on Form 10-Q (collectively the “non-GAAP financial measures”). The presentation of this financial information is not intended to be considered in isolation or as a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP. The Company uses these non-GAAP financial measures for financial and operational decision making and as a means to evaluate period-to-period comparisons. The Company believes that they provide useful information about operating results, enhance the overall understanding of our operating performance and future prospects, and allow for greater transparency with respect to key metrics used by management in its financial and operational decision making. The non-GAAP measures used by the Company in this press release may be different from the measures used by other companies or calculated differently than similar measures used by other companies.
For Investor Relations Inquiries:
Cory Hatton, Head of Entertainment Finance, Investor Relations & Treasurer
Dave & Buster’s Entertainment, Inc. [email protected]
DAVE & BUSTER'S ENTERTAINMENT, INC.
Consolidated Statements of Operations
(unaudited, in millions, except per share amounts)
Three Months Ended May 5, 2026 (1) May 6, 2025 (1)Entertainment revenues$ 345.1 61.7 % $ 366.6 64.6 %Food and beverage revenues 214.1 38.3 % 201.1 35.4 %Total revenues 559.2 100.0 % 567.7 100.0 %Cost of entertainment 27.4 7.9 % 30.6 8.3 %Cost of food and beverage 52.4 24.5 % 51.5 25.6 %Total cost of products 79.8 14.3 % 82.1 14.5 %Operating payroll and benefits 140.1 25.1 % 135.0 23.8 %Other store operating expenses 186.7 33.4 % 188.4 33.2 %General and administrative expenses 27.5 4.9 % 24.4 4.3 %Depreciation and amortization expenses 70.9 12.7 % 63.2 11.1 %Pre-opening costs 5.4 1.0 % 6.1 1.1 %Other charges and gains 1.9 0.3 % 5.3 0.9 %Total operating costs 512.3 91.6 % 504.5 88.9 %Operating income 46.9 8.4 % 63.2 11.1 %Interest expense, net 36.9 6.6 % 36.8 6.5 %Income before income taxes 10.0 1.8 % 26.4 4.7 %Provision for income taxes 4.3 0.8 % 4.7 0.8 %Net income$ 5.7 1.0 % $ 21.7 3.8 % Net income per share: Basic$ 0.16 $ 0.63 Diluted$ 0.16 $ 0.62 Weighted average shares used in per share calculations: Basic shares 34.66 34.72 Diluted shares 34.94 35.19 Other information: Company-owned stores at end of period 244 234 Store operating weeks in the period 3,159 3,018 Total revenue per store operating weeks in the period (in thousands)$ 177 $ 188 Total revenue per square foot per store operating weeks in the period (in dollars)$ 4.32 $ 4.55 (1)All percentages are expressed as a percentage of total revenues for the respective period presented, except cost of entertainment, which is expressed as a percentage of entertainment revenues, and cost of food and beverage, which is expressed as a percentage of food and beverage revenues. DAVE & BUSTER'S ENTERTAINMENT, INC.
Other Operating Data
(unaudited, in millions) Condensed Consolidated Balance Sheets: May 5, 2026
February 3, 2026
ASSETS Cash and cash equivalents$ 19.6 $ 16.6 Other current assets 111.3 107.5 Total current assets 130.9 124.1 Property and equipment, net 1,740.6 1,719.0 Operating lease right of use assets 1,295.1 1,303.2 Intangible and other assets, net 969.2 970.3 Total assets$ 4,135.8 $ 4,116.6 LIABILITIES AND STOCKHOLDERS' EQUITY Total current liabilities$ 451.9 $ 434.6 Deferred income taxes 70.5 68.6 Operating lease liabilities 1,556.3 1,562.6 Other long-term liabilities 462.2 444.6 Long-term debt, net 1,495.3 1,515.0 Stockholders' equity 99.6 91.2 Total liabilities and stockholders' equity$ 4,135.8 $ 4,116.6 Summary Cash Flow Information:
Three Months Ended May 5, 2026 May 6, 2025Net cash provided by (used in): Operating activities:$ 113.8 $ 95.8 Investing activities: (105.3) (154.6)Financing activities: (5.5) 63.8 Increase (decrease) in cash and cash equivalents$ 3.0 $ 5.0 DAVE & BUSTER'S ENTERTAINMENT, INC.
Non-GAAP Measures
(unaudited, in millions)
Adjusted EBITDA:
Adjusted EBITDA represents net income, plus interest expense, net, loss on debt refinancing, provision for income taxes, depreciation and amortization expense, (gain) loss on property and equipment transactions, impairment of long-lived assets, share-based compensation, currency transaction (gains) losses and other costs, as calculated below. Adjusted EBITDA is a non-GAAP financial measure commonly used in our industry and should not be construed as an alternative to net income as an indicator of operating performance or as an alternative to cash flow provided by operating activities as a measure of liquidity (as determined in accordance with GAAP). Adjusted EBITDA may not be comparable to similarly titled measures reported by other companies. Adjusted EBITDA is presented because we believe that it provides useful information to investors and analysts regarding our operating performance. By reporting Adjusted EBITDA, we provide a basis for comparison of our business operations between current, past and future periods by excluding items that we do not believe are indicative of our core operating performance. A reconciliation of net income (loss) to Adjusted EBITDA is provided below for the periods presented:
Three Months Ended May 5, 2026 (1) May 6, 2025 (1)Net income$ 5.7 1.0 % $ 21.7 3.8 %Add back: Interest expense, net 36.9 36.8 Provision for income taxes 4.3 4.7 Depreciation and amortization expense 70.9 63.2 Share-based compensation (2) 2.5 3.0 Transaction and integration costs (3) — 0.2 System implementation costs (4) — 1.5 Other items, net (5) 2.9 5.0 Adjusted EBITDA, a non-GAAP measure$ 123.2 22.0 % $ 136.1 24.0 % (1)All percentages are expressed as a percentage of total revenues for the respective period presented.(2)Non-cash share-based compensation expense, net of forfeitures, recorded in General and administrative expenses on the Consolidated Statements of Comprehensive Income.(3)Transaction and integration costs related to the acquisition and integration of Main Event recorded in Other charges and gains on the Consolidated Statements of Comprehensive Income.(4)System implementation costs represent expenses incurred related to the development and launch of new enterprise resource planning, human capital management and inventory software for our stores and store support teams and staff augmentation for the implementation team at the store support center. These charges are primarily recorded in Other charges and gains on the Consolidated Statements of Comprehensive Income.(5)The amounts for the 2026 periods primarily consisted of severance costs and a loss on property and equipment transactions and other write-offs. The amount for the fiscal 2025 periods primarily consisted of severance costs and a loss on property and equipment transactions other write-offs. The third-party consulting fees for the 2025 period are not part of our ongoing operations and were incurred in association with a change in leadership to execute a discrete, project-based strategic initiative aimed at analyzing and summarizing growth opportunities for the Company. The transformative nature, narrow scope, and limited duration of these incremental consulting fees are not reflective of the ordinary course expenses incurred to operate our business. Loss on property and equipment transactions is included in Other charges and gains on the Consolidated Statements of Comprehensive Income.
Store Operating Income Before Depreciation and Amortization:
Store Operating Income Before Depreciation and Amortization, a non-GAAP measure, represents operating income, plus depreciation and amortization expense, general and administrative expenses, pre-opening costs and other gains and charges. We believe that Store Operating Income Before Depreciation and Amortization is another useful measure in evaluating our operating performance because it removes the impact of general and administrative expenses, which are not incurred at the store level, and the costs of opening new stores, which are non-recurring at the store level, and thereby enables the comparability of the operating performance of our stores for the periods presented. We also believe that Store Operating Income Before Depreciation and Amortization is a useful measure in evaluating our operating performance within the entertainment and dining industry because it permits the evaluation of store-level productivity, efficiency, and performance, and we use Store Operating Income Before Depreciation and Amortization as a means of evaluating store financial performance compared with our competitors. However, because this measure excludes significant items such as general and administrative expenses, pre-opening costs and other gains and charges, as well as our interest expense, net, loss on debt extinguishment/refinance and depreciation and amortization expense, which are important in evaluating our consolidated financial performance from period to period, the value of this measure is limited as a measure of our consolidated financial performance.
Three Months Ended May 5, 2026 (1) May 6, 2025 (1)Operating income$ 46.9 8.4 % $ 63.2 11.1 %Add back: General and administrative expenses 27.5 24.4 Depreciation and amortization expense 70.9 63.2 Pre-opening costs 5.4 6.1 Other Gains and Charges 1.9 5.3 Store operating income before depreciation and amortization, a non-GAAP measure$ 152.6 27.3 % $ 162.2 28.6 % (1)All percentages are expressed as a percentage of total revenues for the respective period presented.
Credit Adjusted EBITDA and Net Total Leverage Ratio:
Credit Adjusted EBITDA, a non-GAAP measure, represents net loss plus certain items as defined at Adjusted EBITDA above, as well as certain other adjustments as defined in our Credit Agreement. These other adjustments include (i) entertainment revenue deferrals, (ii) the cost of new projects, including store pre-opening costs, (iii) business optimization expenses and other restructuring costs, and (iv) other costs and adjustments as permitted by the Credit Agreement. We believe the presentation of Credit Adjusted EBITDA is appropriate as it provides additional information to investors about the calculation of, and compliance with, certain financial covenants in the Credit Agreement. The following table sets forth a reconciliation of Net income to Credit Adjusted EBITDA for the period shown:
Trailing Four Quarters Ended
May 5, 2026Net loss$ (64.7)Add back: Interest expense, net 154.1 Loss on debt refinancing — Provision for income taxes (19.6)Depreciation and amortization expense 287.1 Share-based compensation (1) 19.1 Transaction and integration costs (2) 0.5 System implementation costs (3) 1.8 Loss on property and equipment transactions and impairments (4) 35.0 Other items, net (5) 10.4 Pre-opening costs (6) 18.4 Credit Facility specific items, net (7) 19.8 Credit Adjusted EBITDA, a non-GAAP measure$ 461.9 (1)See discussion of share-based compensation at Adjusted EBITDA above.(2)See discussion of transaction and integration costs at Adjusted EBITDA above.(3)See discussion of system implementation costs at Adjusted EBITDA above.(4)Consists of store asset impairments and loss on property and equipment disposals.(5)Primarily consists of discretionary retention incentives, severance costs, (gain) loss on property and equipment transactions and certain third-party consulting fees. The third-party consulting fees are not part of our ongoing operations and were incurred in association with a change in leadership to execute discrete, project-based strategic initiatives aimed at analyzing and summarizing growth opportunities and cost reductions for the Company. The transformative nature, narrow scope, and limited duration of these incremental consulting fees are not reflective of the ordinary course expenses incurred to operate our business. Third-party consulting fees, discretionary retention incentives and severance costs are included in General and administrative expenses on the Consolidated Statements of Comprehensive Income.(6)Represents costs incurred, primarily consisting of occupancy and payroll related expenses, associated with the opening of new stores. These costs are considered a “cost of new projects” as defined in our Credit Facility.(7)Represents other adjustments allowed under our Credit Agreement in the determination of Net Total Leverage Ratio including (i) amortization of software costs, (ii) executive search fees, (iii) public company costs, (iv) estimated impact of remodels to financial performance, (v) the proforma impact of certain leases that were reclassified as finance leases during fiscal 2025 and (vi) the pro forma impact of certain implemented cost saving initiatives.
The following table provides a calculation of Net Total Leverage Ratio, as defined in the Credit Agreement, for the period shown:
As of, and for the Trailing Four Quarters Ended
May 5, 2026
Credit Adjusted EBITDA (a)$ 461.9 Total debt (1) 1,535.3 Less: Cash and cash equivalents (19.6) Add: Outstanding letters of credit 20.5 Net debt (b)$ 1,536.2 Net Total Leverage Ratio (b / a) 3.3 x (1)Amount represents the face amount of debt outstanding, net of unamortized debt issuance costs and debt discounts, and balances outstanding under finance leases.
Adjusted Net Income and Adjusted Net Income Per Share - Diluted:
Adjusted net income, a non-GAAP measure, represents net income before special items, as calculated below, and Adjusted net income per share - diluted, a non-GAAP measure, represents Adjusted net income on a fully diluted, per share basis. We believe excluding these special items from net income provides investors with a clearer perspective of our ongoing operating performance and a more relevant comparison to prior period results. The following table presents a reconciliation of net income to Adjusted net income and presents Adjusted net income per diluted share, for the periods shown:
Three Months Ended May 5, 2026 May 6, 2025 $ Per Diluted Share $ Per Diluted ShareNet income and net income per diluted share$5.7 $0.16 $21.7 $0.62 Add back: Transaction and integration costs (1) — — 0.2 0.01 System implementation costs (2) — — 1.5 0.04 Other items, net (3) 2.9 0.08 5.0 0.14 Tax impact of items above, net (4) (0.8) (0.02) (1.7) (0.05)Adjusted net income (loss) and Adjusted net income (loss) per share - diluted, non-GAAP measures$ 7.8 $ 0.22 $ 26.7 $ 0.76 (1)See discussion of transaction and integration costs at Adjusted EBITDA above.(2)See discussion of system implementation costs at Adjusted EBITDA above.(3)See discussion of other items, net at Adjusted EBITDA above.(4)The income tax effect related to special items is based on the statutory tax rate for the applicable period.
June 15, 2026 16:05 ET | Source: Applied Materials, Inc.
New systems enable precision materials engineering in high-aspect-ratio 3D logic and memory chip structuresCentris™ Spectral™ SiN ALD leverages innovative microwave plasma technology to deliver uniform silicon nitride deposition in challenging 3D structuresProducer™ Selectra™ Mo Etch selectively removes molybdenum for wordline separation to enable 3D NAND scalingThe new systems are being used by leading logic and memory chipmakers for advanced node manufacturing SANTA CLARA, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- Applied Materials, Inc., the leader in materials engineering for the semiconductor industry, today introduced two new chipmaking systems designed to solve an emerging challenge in leading-edge semiconductor manufacturing: achieving precision processing in increasingly deep and narrow 3D structures. The new deposition and etch systems help chipmakers extend scaling in logic and memory to deliver higher performance, improved energy efficiency, and better manufacturing yield for next-generation AI chips.
The surge in AI compute is accelerating the industry’s transition to advanced 3D device architectures, including gate-all-around (GAA) transistors and high-layer-count 3D NAND. As features become deeper and narrower in these vertical structures, conventional deposition and etch processes struggle to distribute materials uniformly from top to bottom, creating variability that can degrade electrical performance and reduce yield.
To help address this challenge, Applied is introducing Centris™ Spectral™ SiN ALD* and Producer™ Selectra™ Mo Etch. Together, they provide chipmakers with precise control over both dielectric film deposition and metal removal in high-aspect-ratio structures. The result is more uniform materials engineering at advanced nodes, enabling continued 3D scaling with better device performance, tighter process control and improved manufacturability across logic and memory applications.
“As the industry pushes the limits of AI computing, the biggest opportunities are increasingly found in materials engineering,” said Dr. Prabu Raja, President of the Semiconductor Products Group at Applied Materials. “From transistor structures to memory stacks, chipmakers need new ways to precisely deposit and selectively remove materials in extremely complex 3D architectures. With our latest deposition and selective etch systems, we are delivering differentiated capabilities that help customers overcome critical scaling barriers and accelerate the next wave of innovation in logic and memory.”
Centris Spectral SiN ALD Delivers Uniform Deposition in Challenging 3D Structures
Silicon nitride (SiN) is a foundational material for a variety of steps in the chipmaking process, including surface passivation, dielectric isolation and the creation of patterning spacers. These films must be deposited at low temperature to protect neighboring features, and they must be chemically robust to withstand aggressive downstream processing steps.
Conventional plasma-enhanced deposition is not able to uniformly treat the high-aspect-ratio structures in advanced 3D chip architectures, leading to poor-quality SiN films. Centris Spectral SiN ALD solves this issue with an innovative, high-density microwave plasma technology that deposits high-quality SiN within the tall, narrow structures – eliminating the tradeoff between plasma density and ion-induced damage seen in conventional approaches. The system enables dense, uniform SiN deposition at low temperatures, even in challenging 3D structures.
The system has multiple applications that enable continued scaling in both DRAM and logic devices. For example, in GAA transistors, the system can be used to form high-quality liners for transistor contacts that reduce resistance and capacitance at critical interfaces, enabling faster device performance.
Centris Spectral SiN ALD is the latest system based on Applied’s new Spectral ALD platform, a series of ALD tools that feature state-of-the-art quad reactor design with precision chemical delivery, a variety of plasma and thermal processing capabilities, and specialized hardware for both temporal and spatial ALD operation – providing the ability to create a breadth of advanced films to power advanced AI chips.
The Spectral SiN ALD system is being adopted by leading chipmakers. An animation of the system’s capabilities can be viewed here.
Producer Selectra Mo Etch Enables 3D NAND Scaling with Selective Metal Removal
As 3D NAND scales to higher layer counts, new metal integration steps are pushing conventional patterning methods beyond their limits. Low-resistance metals such as molybdenum (Mo) are being adopted for wordline metallization, which requires precise isolation between individual wordlines to prevent electrical shorts and reduce unwanted capacitance. Traditionally, wet etch has been used to separate wordlines, but in today’s tall 3D stacks, liquid chemistries have trouble reaching the full depth of high-aspect-ratio features. This results in top-heavy etch profiles that limit device performance, yield and scalability.
Producer Selectra Mo Etch introduces a new capability for highly selective metal removal, enabling precise, uniform wordline separation across the full stack. Using engineered process control and advanced gas delivery, the system overcomes wet etch limitations to deliver superior top-to-bottom uniformity and tight profile precision in deep features.
By reducing cell-to-cell variability in the 3D NAND stack, the system helps lower leakage and improve data retention. Already validated in high-volume manufacturing, Selectra Mo Etch sets a new benchmark for selective metal etch and enables the transition away from legacy wet processes for continued scaling of next-generation 3D NAND. The new system expands the Selectra portfolio beyond dielectric and silicon applications into advanced metal integration, with new opportunities across NAND, DRAM and foundry-logic.
New Systems To Be Featured at the 2026 VLSI Symposium
Applied is highlighting these innovations in conjunction with the 2026 IEEE Symposium on VLSI Technology & Circuits, where the industry is gathering to discuss advances shaping the future of AI-driven semiconductor innovation. During the conference, Applied is also hosting a panel discussion on June 16 examining how system architectures, logic and memory technologies, advanced packaging, and manufacturing must evolve and co-optimize to enable the next wave of AI-driven compute.
*ALD = Atomic Layer Deposition
About Applied Materials
Applied Materials, Inc. (Nasdaq: AMAT) is the leader in materials engineering solutions that are at the foundation of virtually every new semiconductor and advanced display in the world. The technology we create is essential to advancing AI and accelerating the commercialization of next-generation chips. At Applied, we push the boundaries of science and engineering to deliver material innovation that changes the world. Learn more at www.appliedmaterials.com.
Contact:
Ricky Gradwohl (Media) 408.235.4676
Mike Sullivan (Financial Community) 408.986.7977
NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP highlights the contrast between Zoetis Inc.'s (NYSE: ZTS) promises to investors and the reality that emerged across four corrective disclosures. Shareholders who purchased ZTS securities between January 14, 2025 and May 6, 2026 and suffered losses may be entitled to compensation. Find out if you can recover your investment losses. You may also contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.
Zoetis shares fell $23.91 following the disclosure of intensified competition and slowing growth, a 21.5% single-day decline. The lead plaintiff deadline is July 27, 2026.
The Promise
Throughout the Class Period, Zoetis projected confidence across its Companion Animal portfolio, the lawsuit contends. The Company characterized Librela as "the best launch ever in animal health" with "significant value continuing." Management projected the dermatology total addressable market would reach $2.5 billion by 2028 at an 11% compound annual growth rate. Simparica Trio was described as "the trusted first choice for veterinarians and pet owners alike," and management claimed the franchise was gaining patient share even as competitors entered the market.
The Reality
By Q1 2026, every pillar of this growth narrative had fractured, the complaint alleges:
Librela: Veterinarian adoption weakened sharply following the FDA's December 2024 "Dear Veterinarian" letter citing seizures, paresis, and deaths in treated dogs. Growth deteriorated significantly by Q1 2026Simparica Trio: Lost meaningful market share to Elanco's lower-priced Credelio Quattro, which offered broader tapeworm coverage Trio lackedApoquel / Cytopoint: Suffered substantial share losses to Elanco's Zenrelia, marketed as comparable or superior at a lower price pointPatient Volume: Management admitted "declining patient volume in the clinic" was amplifying share lossesPrice Sensitivity: The Company conceded that "price has played a larger role in the decision process," contradicting prior assertions of brand loyalty insulating the portfolio The Numbers: Promised vs. Actual
Metric What Zoetis Told Investors What Actually Happened Librela
trajectory"Most successful launch in our history"Growth deteriorated significantly; vets became cautious after FDA safety warningsSimparica Trio
share"Continuing to gain share" with 40% puppy penetrationSignificant market share loss to lower-priced competitorDermatology
franchise"Durable" portfolio with "minimal patient share impact" from competitionSubstantial share losses; admitted "derm market with declining patient volume"GuidanceRaised full-year guidance August 2025Sharply reduced guidance May 2026Competitive
impact"Very limited impact" from new entrantsAdmitted competition "intensified across key pet care categories" Speak with an attorney about whether you qualify for recovery or call (212) 363-7500.
What the Lawsuit Alleges About the Gap
"Companies that make specific promises to investors about future performance have an obligation to disclose known risks to those projections. The gap between what Zoetis projected and what materialized raises serious questions about what management knew and when they knew it," stated Joseph E. Levi, Esq.
The action contends that while management publicly projected durable growth, leadership knew or recklessly disregarded that safety concerns, competitive losses, and declining veterinarian confidence were already eroding the foundations of every projection they made to the investing public.
LEAD PLAINTIFF DEADLINE: July 27, 2026
Act now to protect your rights in the Zoetis securities action or contact Joseph E. Levi, Esq. at (212) 363-7500.
Levi & Korsinsky, LLP is a nationally recognized shareholder rights firm. Over the past 20 years, the firm has secured hundreds of millions of dollars for aggrieved shareholders. Ranked in ISS Top 50 for seven consecutive years.
Frequently Asked Questions About the ZTS Lawsuit
Q: When did Zoetis allegedly mislead investors? A: The class period runs from January 14, 2025 to May 6, 2026. During this period, the complaint alleges Zoetis made materially false or misleading statements about its Companion Animal product portfolio's competitive strength and growth sustainability. When the true state was revealed through four corrective disclosures, the stock price declined sharply.
Q: How much did ZTS stock drop? A: Shares fell approximately 21.5% on the final corrective disclosure alone, a decline of $23.91 per share on May 7, 2026.
Q: What do ZTS investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [email protected] or (212) 363-7500. No immediate action is required to remain eligible as a class member.
Q: What if I already sold my ZTS shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold them. Investors who bought during the class period and sold at a loss may still participate.
Q: Do I need to go to court or give testimony? A: No. The overwhelming majority of class members never appear in court or give depositions. You submit a claim form to receive your portion of recovery.
Q: What does it cost me to participate? A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.
Q: What if I missed the lead plaintiff deadline? A: The deadline applies only to investors seeking lead plaintiff appointment. Class members who miss it can still participate in any settlement or recovery.
The logo of the Brucutu mine owned by Brazilian mining company Vale SA is seen in Sao Goncalo do Rio Abaixo, Brazil February 4, 2019. REUTERS/Washington Alves Purchase Licensing Rights, opens new tab
CompaniesRIO DE JANEIRO, June 15 (Reuters) - Brazilian miner Vale (VALE3.SA), opens new tab plans to invest up to 13 billion reais ($2.56 billion) in decarbonization initiatives to meet its voluntary emissions reduction targets and mitigate climate-related risks, a sustainability report showed on Monday.
The company did not specify the timeframe for the investment. The amount includes up to 4 billion reais for decarbonizing operations, with 24% invested in the medium term and 76% in the long term.
The Reuters Power Up newsletter provides everything you need to know about the global energy industry. Sign up here.
Another 8 billion reais is linked to building industrial complexes focused on low-carbon technologies, which includes steelmaking transition technologies and iron ore briquette development.
The remaining 1 billion reais would go for research and development, the firm said.
Vale invested 9 billion reais in decarbonization initiatives from 2020 to 2025.
Through these initiatives, Vale sees potential for financial and environmental returns for its business, Grazielle Parenti, executive vice president of sustainability, said in an interview with Reuters.
"Within Vale's governance framework, all projects and decisions of this caliber are evaluated using an environmental, social, and governance matrix that identifies potential risks and opportunities for each one," she said.
The company also warned on Monday it could face carbon costs of up to 22 billion reais at present value from carbon pricing mechanisms, with substantial impacts expected from 2030 onwards.
($1 = 5.0686 reais)
Reporting by Marta Nogueira; Writing by Fernando Cardoso; Editing by Aurora Ellis
Our Standards: The Thomson Reuters Trust Principles., opens new tab
Western Digital shares are testing new highs. What’s driving WDC to record levels? The call follows a week of management meetings and Asia checks that strengthened his conviction that Western Digital will continue to outperform on the back of 30%+ year‑over‑year nearline enterprise growth, accelerating pricing, expanding margins and improving operating leverage.
Stronger Outlook And Valuation ResetWoodring raised his FY27 and FY28 earnings estimates to $22.40 and $43.47, now 30–70% above consensus. His new target implies roughly 20× CY27 EPS of $32.29, and he sees a path for shares to effectively double over the next year if his bull‑case pricing assumptions play out.
He also highlighted Western Digital's dual‑tracked UltraSMR/HAMR roadmap, which he believes investors continue to under‑appreciate, calling it a source of reliability and strength rather than a technology gap versus peers.
Critical Technical Levels for WDC StockWDC remains in a powerful uptrend. The stock trades 25.1% above its 20‑day simple moving average at $518.10, 44.4% above its 50‑day at $449.12, and 155.5% above its 200‑day at $253.77. That level of separation signals strong long‑term demand but also raises the risk of sharp pullbacks if buyers pause.
The moving‑average structure stays bullish, with the 20‑day above the 50‑day and a golden cross from July 2025 still intact. However, MACD has slipped below its signal line and the histogram is negative, a classic momentum‑cooling setup even as price holds elevated. The rally can continue, but it now depends more on fresh buying to sustain upside pressure.
Technically, WDC has cleared its prior 52‑week high at $602.54, which can flip from resistance into support if price retests it. The most recent swing high was set in June and the swing low in March, meaning the current advance extends a multi‑month uptrend rather than reversing weakness.
Key Resistance: $602.54 — prior 52-week high from June that price has now cleared, making it a key "hold-above" level Key Support: $518.10 — near the 20-day SMA, a common first pullback area in strong uptrends WDC Shares Are SoaringWDC Price Action: Western Digital shares were up 14.70% at $645.69 at the time of publication on Monday. The stock is trading at a new 52-week high, according to Benzinga Pro.
Image: T. Schneider/Shutterstock
Market News and Data brought to you by Benzinga APIs
Department staffers investigating the Warner acquisition were leaning toward recommending a challenge to the merger, people familiar with the matter say.
Tom White breaks down stocks on the move and shows unusual options trades he found for all his picks. He says Alphabet's (GOOGL) recent rally has more room to run, Rocket Lab (RKLB) will have more muscle due to its Nasdaq-100 (NDX) inclusion, and KLA Corp. (KLAC) gaining more interest as shares hit an all-time high.
Androstenedione and other adrenal hormone levels in 11β‑hydroxylase-deficient patients improved substantially after initiation of CRENESSITY, with >90% median reductions in 11-deoxycortisol and 11-deoxycorticosterone Nearly all patients (14/15) reduced their total glucocorticoid dose with CRENESSITY, and 2 of 5 patients on antihypertensive medications reduced or discontinued these drugs Findings provide initial clinical insights in patients with classic congenital adrenal hyperplasia due to 11β-hydroxylase deficiency, a rare subtype not previously studied in clinical trials of CRENESSITY , /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced clinical findings from the first retrospective case series in pediatric and adult patients with classic congenital adrenal hyperplasia (CAH) due to 11β‑hydroxylase deficiency. This subtype was not previously studied in clinical trials of CRENESSITY® (crinecerfont) and is the second most common form of classic CAH after 21-hydroxylase deficiency, accounting for approximately 5% of cases. The findings were presented at the Endocrine Society's annual meeting, ENDO 2026, in Chicago.
Like other forms of CAH, 11β‑hydroxylase deficiency (11β‑OHD) is characterized by cortisol deficiency and excess adrenal androgens. However, 11β‑OHD is uniquely associated with the accumulation of the adrenal steroid precursors 11-deoxycortisol (11-dF) and 11-deoxycorticosterone (DOC). These hormonal imbalances can contribute to distinct clinical features, including hypertension and other long‑term complications. In this retrospective case series, reductions in androstenedione (A4) were observed across all patients with elevated baseline levels following initiation of CRENESSITY. Steroid precursors also decreased, with values reaching within normal ranges, and blood pressure improved in adult patients.
"Patients with 11β‑hydroxylase deficiency represent a complex subgroup within classic congenital adrenal hyperplasia, with limited data available to guide treatment decisions for these individuals," said Sanjay Keswani, M.D., Chief Medical Officer, Neurocrine Biosciences. "This first case series provides preliminary clinical insights on the use of CRENESSITY to target ACTH and potentially improve hormonal control in patients with 11β‑hydroxylase deficiency, highlighting our ongoing commitment to advancing care for the entire classic CAH community."
This retrospective case series outlines clinical responses to CRENESSITY treatment in 15 pediatric (n=11) and adult (n=4) patients with classic CAH due to 11β‑OHD. Across all patients with elevated A4 and/or adrenal steroid precursors at baseline, initiation of CRENESSITY was associated with reduction of levels.
A4 and precursor normalization were observed as early as one month following treatment initiation, including in patients whose hormone excess had persisted despite prior supraphysiologic glucocorticoid (GC) therapy. Among patients with elevated hormones at baseline, median decreases of -92% (DOC, n=5), -95% (11‑dF, n=7), and -65% (A4, n=3) were observed after CRENESSITY initiation. Among patients receiving antihypertensive treatment, two of five were able to reduce or discontinue these medications. Following the initiation of CRENESSITY, 14 of 15 patients were able to reduce their total GC dose. "Patients with 11β-hydroxylase deficiency often experience both androgen excess and elevated adrenal steroid precursors that can contribute to hypertension and other complications, making disease management particularly challenging," said Kyriakie Sarafoglou, M.D., Professor, Department of Pediatrics and Department of Experimental and Clinical Pharmacology, Divisions of Endocrinology and Genetics & Metabolism, University of Minnesota. "Given the rarity of this condition, data from 15 patients gives clinicians meaningful insight into the potential role of CRENESSITY in managing this challenging form of classic congenital adrenal hyperplasia."
This case series provides early, foundational evidence supporting the efficacy and safety of CRENESSITY treatment in patients with classic CAH due to 11β-OHD. Although CRENESSITY is approved as an adjunctive treatment to GCs for patients with classic CAH regardless of enzyme deficiency, there is limited evidence on its use in this rare subtype. These findings support further exploration of CRENESSITY in this classic CAH subtype and reinforce Neurocrine's commitment to supporting patients across the full spectrum of classic CAH and other rare endocrine diseases.
Presentations at the ENDO 2026 annual meeting included:
CAHtalyst® Adult Study Two-Year Results
Title: Weight-Related Outcomes and Insulin Resistance in Adults with Classic Congenital Adrenal Hyperplasia: 2-Year Results from the CAHtalyst Adult Study (Oral Presentation #ORF32-07)
Authors: Oksana Hamidi, D.O., et al
Title: Adults with Classic Congenital Adrenal Hyperplasia Taking Crinecerfont Demonstrated Sustained Decreases in Glucocorticoid Doses: 2-Year Results from the CAHtalyst Adult Study (Poster Presentation #SUN-458)
Authors: Irina Bancos, M.D., et al
Title: A Cross-sectional Survey on Quality of Life of Adults with Classic Congenital Adrenal Hyperplasia in the United States Participating in CAHtalyst Adult Open-Label Extension Study (Poster Presentation #SUN-467)
Authors: Sonal Vaid, M.D., et al
Title: Bone Outcomes in Adults with Classic Congenital Adrenal Hyperplasia Treated with Crinecerfont for Up to 2 Years in CAHtalyst Adult Study (Poster Presentation #SUN-468)
Authors: Maria Vogiatzi, M.D., et al
CAHtalyst Pediatric Study Two-Year Results
Title: Characterization of Children and Adolescents with Classic Congenital Adrenal Hyperplasia Who Had Slowed Bone Age Progression and Improved Height Prediction with Crinecerfont (Oral Presentation #ORF32-05)
Authors: Maria Vogiatzi, M.D., et al
Title: Long-term Crinecerfont Treatment Reduced ACTH and 17-Hydroxyprogesterone — Clinical Outcomes in Children and Adolescents with Classic Congenital Adrenal Hyperplasia: 2-Year Results from CAHtalyst Pediatric (Poster Presentation #SAT-465)
Authors: Natalie Nokoff, M.D., et al
Title: Long-term Crinecerfont Enables Sustained Decreases in Glucocorticoid Doses — Clinical Outcomes in Children and Adolescents with Classic Congenital Adrenal Hyperplasia: 2-Year Results from CAHtalyst Pediatric (Poster Presentation #SUN-465)
Authors: Kyriakie Sarafoglou, M.D., et al
Additional Presentations
Title: Long-Term Risk of Cardiometabolic Comorbidities Associated with Glucocorticoid Exposure and Androgen Control in Classic Congenital Adrenal Hyperplasia: A Cox Proportional Hazards Analysis from the CAHtalog Registry ("New Therapies and Perspectives for Congenital Adrenal Hyperplasia and Adrenal Insufficiency" Rapid Fire Presentation #ORF32-02 and Poster Presentation #MON-495)
Authors: Oksana Lekarev, D.O., et al
Title: Crinecerfont Treatment of Classic Congenital Adrenal Hyperplasia Due to 11β-Hydroxylase Deficiency: A Case Series (Poster Presentation #SAT-466)
Authors: Kyriakie Sarafoglou, M.D., et al
Title: A Modified Delphi Panel of U.S. Endocrinologists to Align on Minimum Clinically Important Difference in Glucocorticoid Dose and Other Key Considerations in Classic Congenital Adrenal Hyperplasia (Poster Presentation #SAT-459)
Authors: Ahmed Khattab, M.D., et al
About Congenital Adrenal Hyperplasia
Congenital adrenal hyperplasia (CAH) is a rare genetic condition that results in an enzyme deficiency that alters the production of adrenal steroid hormones, such as cortisol, aldosterone and adrenal androgens. Severe enzyme deficiency leads to an inability of the adrenal glands to produce enough cortisol and, in approximately 75% of cases, aldosterone. Because individuals with CAH are typically still able to produce androgens, the unused precursors that would normally be used to make cortisol instead result in the production of excess amounts of androgens. If left untreated, CAH can result in adrenal crisis and even death.
Exogenous glucocorticoids (GCs) are necessary to correct the endogenous cortisol deficiency, but historically, doses higher than those needed for cortisol replacement (supraphysiologic) have been used to lower the elevated levels of adrenocorticotropic hormone (ACTH) and adrenal androgens. However, GC treatment at supraphysiologic doses has been associated with serious and significant complications of steroid excess, including metabolic issues such as weight gain and diabetes, cardiovascular disease and osteoporosis. Additionally, long-term treatment with supraphysiologic GCs may have psychological and cognitive impacts, such as changes in mood and memory. Adrenal androgen excess has been associated with abnormal bone growth and development in pediatric patients, female health problems such as excess facial hair growth and menstrual irregularities, in addition to cardiometabolic and fertility issues in both sexes. The symptoms of high ACTH may include testicular adrenal rest tumors (TARTs).
About CRENESSITY® (crinecerfont)
CRENESSITY is a potent and selective oral corticotropin-releasing factor type 1 receptor (CRF1) antagonist that reduces and controls excess adrenocorticotropic hormone (ACTH) and adrenal androgens through a non-glucocorticoid (GC) mechanism for the treatment of classic congenital adrenal hyperplasia (CAH). Antagonism of CRF1 receptors in the pituitary has been shown to decrease ACTH levels, which in turn decreases the production of adrenal androgens and potentially the symptoms associated with CAH. The robust clinical study data demonstrate that lowering adrenal androgen levels with CRENESSITY enables lower, more physiologic dosing of GCs to replace missing cortisol.
CRENESSITY comes in capsules and an oral solution. For adults 18 years of age and older, the recommended dosage is 100 mg twice daily taken orally with a meal. For pediatric patients four to 17 years of age weighing less than 55 kg (121 lbs), the recommended dosage is based on body weight and is administered twice daily, taken orally with a meal. For pediatric patients weighing more than 55 kg (121 lbs), the recommended dosage is 100 mg twice daily taken orally with a meal. Healthcare providers can work with patients to determine the appropriate formulation for use depending on patient needs. Patients receiving CRENESSITY should continue GC therapy for cortisol replacement.
About the CAHtalyst® Studies
The Phase 3 CAHtalyst global registrational studies were designed to evaluate the safety, efficacy and tolerability of CRENESSITY® (crinecerfont) in children and adults with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. The CAHtalyst studies were the largest-ever clinical trial program in classic CAH, including 285 pediatric and adult patients.
The CAHtalyst Pediatric study included 103 pediatric patients four to 17 years of age. The study tested two questions. The first question evaluated whether four weeks of CRENESSITY treatment could improve androgen control. The second question evaluated whether an additional 24 weeks of CRENESSITY treatment enabled customized glucocorticoid (GC) down-titration while androstenedione levels were maintained or improved.
The CAHtalyst Adult study included 182 adult patients 18 to 58 years of age. Similarly, the first question of the study evaluated whether four weeks of CRENESSITY treatment could improve androgen control, and the second question evaluated whether an additional 20 weeks of CRENESSITY treatment enabled GC reduction to physiologic range while androstenedione levels were maintained or improved.
Data from the CAHtalyst Phase 3 studies supported approval of CRENESSITY by the U.S. Food and Drug Administration in December 2024. The open-label extension treatment portions of both studies are ongoing.
Important Information
Approved Uses
CRENESSITY® (crinecerfont) is a prescription medicine used together with glucocorticoids (steroids) to control androgen (testosterone-like hormone) levels in adults and children 4 years of age and older with classic congenital adrenal hyperplasia (CAH).
IMPORTANT SAFETY INFORMATION
Do not take CRENESSITY if you:
Are allergic to crinecerfont, or any of the ingredients in CRENESSITY.
CRENESSITY may cause serious side effects, including:
Allergic reactions. Symptoms of an allergic reaction include tightness of the throat, trouble breathing or swallowing, swelling of the lips, tongue, or face, and rash. If you have an allergic reaction to CRENESSITY, get emergency medical help right away and stop taking CRENESSITY.
Risk of Sudden Adrenal Insufficiency or Adrenal Crisis with Too Little Glucocorticoid (Steroid) Medicine. Sudden adrenal insufficiency or adrenal crisis can happen in people with congenital adrenal hyperplasia who are not taking enough glucocorticoid (steroid) medicine. You should continue taking your glucocorticoid (steroid) medicine during treatment with CRENESSITY. Certain conditions such as infection, severe injury, or shock may increase your risk for sudden adrenal insufficiency or adrenal crisis. Tell your healthcare provider if you get a severe injury, infection, illness, or have planned surgery during treatment. Your healthcare provider may need to change your dose of glucocorticoid (steroid) medicine.
Before taking CRENESSITY, tell your healthcare provider about all of your medical conditions, including if you: are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed.
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins and herbal supplements.
The most common side effects of CRENESSITY in adults include tiredness, headache, dizziness, joint pain, back pain, decreased appetite, and muscle pain.
The most common side effects of CRENESSITY in children include headache, stomach pain, tiredness, nasal congestion, and nosebleeds.
These are not all the possible side effects of CRENESSITY. Call your healthcare provider for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.
Dosage Forms and Strengths: CRENESSITY is available in 50 mg and 100 mg capsules, and as an oral solution of 50 mg/mL.
Please see full Prescribing Information.
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For more than three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, Facebook and YouTube. (*in collaboration with AbbVie)
The NEUROCRINE BIOSCIENCES Logo, NEUROCRINE, YOU DESERVE BRAVE SCIENCE, CRENESSITY and CAHtalyst are registered trademarks of Neurocrine Biosciences, Inc.
Forward-Looking Statements
In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the potential benefits to be derived from CRENESSITY for the treatment of classic congenital adrenal hyperplasia (CAH); the value and benefits CRENESSITY brings to patients with CAH, including its potential to target adrenocorticotropic hormone (ACTH) and improve hormonal control in patients with CAH due to 11β-hydroxylase deficiency; the ability of Neurocrine Biosciences to ensure patients have access to CRENESSITY; and whether the results from our clinical trials of CRENESSITY are indicative of real-world results. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following: risks and uncertainties as to whether the data described in this press release will be replicated in additional studies or will be predictive of efficacy or other clinical outcomes in subsequent clinical studies or real-world use of CRENESSITY; risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, as well as risks and uncertainties associated with the commercialization of CRENESSITY, including the extent to which patients and physicians accept and adopt CRENESSITY; whether CRENESSITY receives adequate reimbursement from third-party payors; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY; risks associated with the Company's dependence on third parties for development and manufacturing activities related to CRENESSITY, and the ability of the Company to manage these third parties; risks that additional regulatory submissions for CRENESSITY may not occur or be submitted in a timely manner; risks that the FDA or other regulatory authorities may make adverse decisions regarding CRENESSITY; risks that post-approval CRENESSITY commitments or requirements may be delayed; risks that CRENESSITY may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks and uncertainties relating to competitive products and technological changes that may limit demand for CRENESSITY; and other risks described in the Company's periodic reports filed with the Securities and Exchange Commission, including without limitation the Company's quarterly report on Form 10-Q for the quarter ended March 31, 2026. Neurocrine Biosciences disclaims any obligation to update the statements contained in this press release after the date hereof other than required by law.
Participants who resumed VYKAT XR following a 16-week randomized withdrawal period demonstrated improvements in hyperphagia and behavioral symptoms as early as Week 13, with benefits continuing through 2 years VYKAT XR demonstrated statistically significant and sustained improvements in hyperphagia and Prader-Willi syndrome-related behaviors for up to 3 years compared to real-world data from the PATH for PWS Natural History Study , /PRNewswire/ -- Soleno Therapeutics, a Neurocrine Biosciences (Nasdaq: NBIX) company, today announced late-breaking data at ENDO 2026 showing that resuming treatment with VYKAT® XR (diazoxide choline) extended-release tablets for two years after a 16-week randomized withdrawal period was associated with durable improvements in hyperphagia and behavioral symptoms characteristic of Prader-Willi syndrome (PWS).
"These compelling data further reinforce our confidence in VYKAT XR as a safe and effective long-term treatment for hyperphagia in individuals four years of age and older living with Prader-Willi syndrome," said Sanjay Keswani, M.D., Chief Medical Officer, Neurocrine Biosciences. "Individuals who resumed treatment following the randomized withdrawal period achieved durable improvements in hyperphagia and other PWS-related behaviors. This completes the presentation of data from our comprehensive Phase 3 development program and further confirms the long-term benefit of VYKAT XR for people living with PWS."
The VYKAT XR Phase 3 development program was conducted sequentially, including:
A 13-week randomized, double-blind, parallel-arm study (C601) comparing VYKAT XR to placebo in participants four years of age and older with hyperphagia associated with genetically confirmed PWS An open-label extension study (C602 OLE) over approximately two to four years A 16-week, double-blind, placebo-controlled randomized withdrawal period An open-label long-term extension study (C614) Study C614, the open-label long-term extension study, enrolled 77 participants (mean age, 15.3 years; 55.8% female). The study assessed whether participants who had received placebo during the randomized withdrawal period could regain treatment benefit after restarting VYKAT XR, and whether participants who remained on continuous VYKAT XR maintained benefit over time.
Hyperphagia was assessed using the Hyperphagia Questionnaire for Clinical Trials (HQ-CT) and PWS-related behaviors were assessed using the PWS Profile questionnaire (PWSP). BMI and long-term safety were also assessed. Study results included:
Participants who restarted VYKAT XR after placebo during the randomized withdrawal showed marked improvements in HQ-CT Total Score by Week 13 (mean [SD], -4.5 [6.3]), with further improvement observed at Week 26 and at two years (-5.5 [7.1] and -6.3 [8.4], respectively). Participants who remained on VYKAT XR continuously showed smaller improvements (-2.7 [6.9]) at Week 13 that were sustained at Week 26 and at two years (-3.3 [5.7] and -3.1 [8.0], respectively), underscoring the benefit of uninterrupted therapy. Improvements across all six PWSP behavioral domains were observed at two years in participants who restarted VYKAT XR, and BMI remained relatively stable throughout. These data show that participants who resumed VYKAT XR after randomized withdrawal experienced recovery of treatment benefit, while those who continued therapy maintained durable improvements in hyperphagia and other PWS-related behaviors. Study results were presented as, "Efficacy and Safety of Resuming Diazoxide Choline Extended-Release (DCCR) after 16-week Randomized Withdrawal in Prader-Willi Syndrome (Study C614)," which was authored by Jennifer L. Miller, M.D., University of Florida, Gainesville.
Additional presentations at ENDO 2026:
VYKAT XR Outcomes Compared to Real-World Data from PATH for PWS Natural History Study (PATH):
Long-Term Reductions in Hyperphagia: HQ-CT Analysis
A poster presentation led by Evelien F. Gevers, M.D., Ph.D., Barts Health NHS Trust/Queen Mary University of London, reported three-year data comparing 125 VYKAT XR-treated participants from Studies C601 and C602-OLE to 229 natural history controls from the PATH for PWS Natural History Study. VYKAT XR demonstrated statistically significant and sustained improvements in hyperphagia compared with the PATH cohort at all evaluated time points (p<0.0001), with treatment differences of 6.2 points at Year 1, 6.5 points at Year 2, and 6.2 points at Year 3 on the HQ-CT Total Score.
Long-Term Behavioral Improvements: PWSP Analysis
A second presentation by Dr. Gevers reported PWSP data comparing 105 VYKAT XR-treated participants to 182 PATH controls over three years. Statistically significant improvements favoring VYKAT XR compared with the PATH cohort were observed across all six behavioral domains at Year 1 (p<0.001), Year 2 (p<0.01), and Year 3 (p<0.001). At Year 3, VYKAT XR demonstrated consistent improvements across all assessed behavioral domains versus the PATH cohort, with adjusted mean differences favoring VYKAT XR of -2.5 in anxiety, -2.4 in rigidity/irritability, -2.3 in compulsivity, -2.1 in aggressive behaviors, -1.5 in disordered thinking, and -1.1 in depression.
About PWS
Prader-Willi syndrome (PWS) is a rare genetic neurodevelopmental disorder caused by an abnormality in the gene expression on chromosome 15. The Prader-Willi Syndrome Association USA estimates that PWS occurs in one in every 15,000 live births. The defining symptom of PWS is hyperphagia, a chronic and life-threatening condition characterized by an intense persistent sensation of hunger accompanied by food preoccupations, an extreme drive to consume food, food-related behavior problems, and a lack of normal satiety, which can severely diminish the quality of life for individuals with PWS and their families. Hyperphagia can lead to significant mortality (e.g., stomach rupture, choking, accidental death due to food seeking behavior) and longer term, co-morbidities such as diabetes, obesity, and cardiovascular disease.
About VYKAT® XR
VYKAT XR was approved by the U.S. Food and Drug Administration (FDA) on March 26, 2025, and is now commercially available to U.S. patients.
VYKAT XR is indicated for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome (PWS).
IMPORTANT SAFETY INFORMATION
Contraindications
Use of VYKAT XR is contraindicated in patients who have a known hypersensitivity to diazoxide, other components of VYKAT XR, or to thiazides.
Warnings and Precautions
Hyperglycemia
Hyperglycemia, including diabetic ketoacidosis, has been reported. Before initiating VYKAT XR, test fasting plasma glucose (FPG) and HbA1c; optimize blood glucose in patients who have hyperglycemia. During treatment, regularly monitor fasting glucose (FPG or fasting blood glucose) and HbA1c. Monitor fasting glucose more frequently during the first few weeks of treatment in patients with risk factors for hyperglycemia.
Risk of Fluid Overload
Edema, including severe reactions associated with fluid overload, has been reported. Monitor for signs or symptoms of edema or fluid overload. VYKAT XR has not been studied in patients with compromised cardiac reserve and should be used with caution in these patients.
Adverse Reactions
The most common adverse reactions (incidence ≥10% and at least 2% greater than placebo) included hypertrichosis, edema, hyperglycemia, and rash.
Please see the full Prescribing Information, including Medication Guide.
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences is a leading biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering, developing and commercializing life-changing treatments for patients with under-addressed neurological, psychiatric, endocrine and immunological disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, hyperphagia in patients with Prader-Willi syndrome, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For more than three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, Facebook and YouTube. (*in collaboration with AbbVie)
The NEUROCRINE BIOSCIENCES Logo, NEUROCRINE and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc. SOLENO and VYKAT are registered trademarks of Soleno Therapeutics, Inc.
Forward-Looking Statements
In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the potential benefits to be derived from VYKAT XR for the treatment of Prader-Willi syndrome (PWS); the value and benefits VYKAT XR brings to patients with PWS, including its potential to support sustained and durable improvements in hyperphagia and PWS-related behavioral symptoms; and whether the results from clinical studies and other data analyses described in this press release are indicative of real-world results. Factors that could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following: risks and uncertainties as to whether the data described in this press release will be replicated in additional studies or will be predictive of efficacy, safety, or other clinical outcomes in subsequent clinical studies or real-world use of VYKAT XR; risks and uncertainties associated with our business and finances in general, as well as risks and uncertainties associated with the commercialization of VYKAT XR, including the extent to which patients and physicians accept and adopt VYKAT XR; whether VYKAT XR receives adequate coverage and reimbursement from third-party payors; risks and uncertainties relating to competitive products and technological changes that may limit demand for VYKAT XR; risks associated with dependence on third parties for development and manufacturing activities related to VYKAT XR, and risks associated with managing these third parties; risks that additional regulatory submissions for VYKAT XR may not occur or be submitted in a timely manner; risks that the FDA or other regulatory authorities may make adverse decisions regarding VYKAT XR; risks that post-approval commitments or requirements for VYKAT XR may be delayed; risks that VYKAT XR may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and other risks described in Neurocrine Biosciences' periodic reports filed with the Securities and Exchange Commission, including without limitation Neurocrine Biosciences' quarterly report on Form 10-Q for the quarter ended March 31, 2026, and with respect to risks relating to VYKAT XR and Soleno Therapeutics, certain risks described in Soleno Therapeutics' annual report on Form 10-K for the year ended December 31, 2025, as updated by Soleno Therapeutics' quarterly report on Form 10-Q for the quarter ended March 31, 2026. Neurocrine Biosciences and Soleno Therapeutics disclaim any obligation to update the statements contained in this press release after the date hereof except as required by law.
The natural gas market has been transformed in recent decades from fracking and transportation advances, which have made natural gas far more of a global energy source. FLEX LNG (FLNG 3.23%) and Targa Resources (TRGP 3.77%) offer distinct ways to play the natural gas market. Which is the better buy today?
FLEX LNG focuses on the global ocean transport of deeply cooled natural gas, while Targa Resources provides the essential pipes and processing plants on American soil. Both companies benefit from rising export demand, but they operate at very different scales. This comparison of their financials and risks helps determine which stock fits your strategy.
The case for FLEX LNGFLEX LNG operates as a pure-play shipping company specializing in the ocean transport of liquefied natural gas using a fleet of 13 carriers. These vessels provide the vital link between gas producers and global consumers by delivering massive loads of around 174,000 cubic meters of LNG, enough to power 45,000 homes for a year. Its standardized, modern fleet helps the company maintain a competitive edge over older, less efficient ships while ensuring reliable delivery for its customers.
In FY 2025, revenue reached nearly $335.3 million, a decrease of about $17 million from the prior year. The company reported net income of roughly $74.8 million, a 36% decline from 2024.
As of its December 2025 balance sheet, the debt-to-equity ratio was nearly 2.6x, indicating a reliance on borrowed funds. The current ratio, which measures the ability to pay short-term obligations using current assets, was a robust 3.0x. Free cash flow, calculated as cash from operations minus capital expenditures, was approximately $134.9 million and supports the ongoing maintenance of its modern vessel fleet.
The case for Targa ResourcesTarga Resources operates a vast network of midstream infrastructure across several major U.S. shale plays, including the Permian Basin and the Bakken. The company gathers, processes, and transports natural gas to domestic and international markets, making it a critical part of the natural gas market. This integrated model uses thousands of employees to manage extensive physical assets that connect American energy production to Gulf Coast export channels.
For FY 2025, revenue was nearly $17.1 billion, reflecting a year-over-year growth rate of approximately 3.1%. Net income for the period was close to $1.85 billion, which achieved a net margin of roughly 10.8%. This margin represents the percentage of revenue retained as profit and reflects the high costs of operating massive physical pipelines and processing plants.
According to its December 2025 balance sheet, the debt-to-equity ratio was approximately 5.7x, indicating that total debt is more than five times the value of shareholder equity. The current ratio of 0.7x indicates that short-term liabilities exceed current assets, while free cash flow reached roughly $584.1 million. This cash flow figure, which is derived by subtracting capital expenditures from operating cash flow, provides the company with liquidity for its operations.
Risk profile comparisonFLEX LNG faces risks primarily tied to the volatility of global shipping rates and fleet utilization, which can decline if vessel supply exceeds demand. Any disruption in international trade routes or geopolitical tensions near major ports could impact its operations and revenue generation. The company is also subject to environmental regulations that could eventually force expensive upgrades to its carriers to meet new standards.
Targa Resources is sensitive to commodity price volatility and faces competition from large rivals like Enterprise Products Partners (EPD 2.01%) and Kinder Morgan Partners (KMI 1.60%). Operational hazards, such as pipeline leaks, cyberattacks, and evolving climate regulations, also pose significant financial risks to its daily operations. Additionally, the company relies on third-party storage infrastructure, and any lack of access to these facilities could adversely impact its bottom line.
Valuation comparisonFLEX LNG appears cheaper on a Forward P/E basis, while Targa Resources offers a more attractive P/S ratio based on its total sales volume.
MetricFLEX LNGTarga ResourcesSector BenchmarkForward P/E13.223.8x21.4xP/S ratio4.6x3.3xSector benchmark uses the SPDR XLE sector ETF.
Valuation metrics sourced from Financial Modeling Prep (FMP) and may differ from other data providers.
One of the great appeals of midstream oil and gas stocks is that they are more insulated from the volatility of energy prices than other parts of the energy system, such as wildcatters, refiners, and retailers.
Targa Resources is a more traditional midstream infrastructure play, as one of the largest independent gathering and distribution pipeline systems in the U.S. In particular, Targa is the largest pipeline operator in the Permian Basin and can transport natural gas from that region and other producing areas, such as the Bakken, to key distribution centers along the Gulf Coast.
For fiscal year 2026, the company is expected to see a robust increase in revenue of around 18%, to more than $20 billion, with improved net income of $2.58 billion, up around $250 million. The war in the Middle East, which has driven up global energy prices and disrupted supply, is a tailwind for demand, which the company is meeting with the opening of two additional processing hubs this year.
FLEX LNG is an intriguing story: the expansion of U.S. natural gas production and the increase in long-haul global LNG shipments, driven by supply changes from the Iran War and other macro factors, should benefit FLEX. But the fact of the matter is, there are too many LNG tankers coming into the market right now to generate a meaningful bump in near-term spot rates for the handful of ships FLEX is marketing (the bulk of the fleet is tied to long-term delivery contracts). Long-term, the structural shift in European demand away from Russia and toward the U.S. is something to watch for FLEX LNG, but for investors seeking a natural gas stock benefiting from today’s market conditions. Targa Resources is the choice.
Centene said it offered buyouts to some employees on Monday, as the health insurer grapples with higher medical costs, funding cuts and membership declines.
"Centene is positioning the company to lead the future of healthcare - working to deliver a simpler and better experience for our members and partners while meeting the realities of today's healthcare environment," a company spokesperson said in a statement. "Today we announced a Voluntary Separation Program to support employees who may be considering a transition."
The company did not indicate how many employees it offered buyouts to, or how much it is aiming to reduce its workforce. Shares initially fell 4% after Bloomberg first reported the news on Monday.
Layoffs could follow if the company doesn't meet the target for voluntary separations, Bloomberg reported.
Centene is the largest Medicaid provider and is focused on other federal health plans through Medicare and the Affordable Care Act. The buyouts come after the company reported a decline in membership in the first quarter, down 6% year-over-year to 26.3 million, according to a filing.
Centene's ACA business lost about 2 million members in the first quarter compared to the end of 2025, primarily because Congress let enhanced federal subsidies in the program expire at the start of the year. The company in March also said it expects ACA membership to fall nearly 40% by the end of 2026, executives said in March at a Barclays conference.
Centene is bracing for the impact of more than $900 billion in cuts to Medicaid over a decade, and the broader insurance industry is still managing higher-than-expected medical costs in privately run Medicare plans.
KANSAS CITY, Mo.--(BUSINESS WIRE)--EPR Properties (NYSE:EPR) today announced that its Board of Trustees has declared its monthly cash dividend to common shareholders. The dividend of $0.31 per common share is payable July 15, 2026 to shareholders of record on June 30, 2026. This dividend represents an annualized dividend of $3.72 per common share.
The Board of Trustees also declared quarterly dividends to preferred shareholders:
5.75% Series C Cumulative Convertible Preferred Shares (NYSE:EPRprC): The Company declared a dividend of $0.359375 per share payable July 15, 2026 to shareholders of record on June 30, 2026.9.00% Series E Cumulative Convertible Preferred Shares (NYSE:EPRprE): The Company declared a dividend of $0.5625 per share payable July 15, 2026 to shareholders of record on June 30, 2026.5.75% Series G Cumulative Redeemable Preferred Shares (NYSE:EPRprG): The Company declared a dividend of $0.359375 per share payable July 15, 2026 to shareholders of record on June 30, 2026.About EPR Properties
EPR Properties (NYSE:EPR) is the leading diversified experiential net lease real estate investment trust (REIT), specializing in select enduring experiential properties in the real estate industry. We focus on real estate venues which create value by facilitating out of home leisure and recreation experiences where consumers choose to spend their discretionary time and money. We have total assets of approximately $5.7 billion (after accumulated depreciation of approximately $1.8 billion) across 42 states and Canada. We adhere to rigorous underwriting and investing criteria centered on key industry, property and tenant level cash flow standards. We believe our focused approach provides a competitive advantage and the potential for stable and attractive returns. Further information is available at www.eprkc.com.
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz reminds investors of the upcoming June 22, 2026 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired LKQ Corporation (“LKQ” or the “Company”) (NASDAQ: LKQ) common stock between February 27, 2023 and July 23, 2025, inclusive (the “Class Period”).IF YOU ARE AN INVESTOR WHO LOST MONEY ON LKQ CORPORATION (LKQ), CLICK HERE TO PARTICIPATE IN THE SECURITIES FRAUD.
, /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Dana Incorporated (NYSE: DAN) related to its sale to Eaton Corporation plc. Upon closing of the proposed transaction, Dana shareholders will own approximately 49.9% of the combined company. Is it a fair deal?
Click here for more info https://monteverdelaw.com/case/dana-incorporated/. It is free and there is no cost or obligation to you.
NOT ALL LAW FIRMS ARE EQUAL. Before you hire a law firm, you should talk to a lawyer and ask:
Do you file class actions and go to Court? When was the last time you recovered money for shareholders? What cases did you recover money in and how much? About Monteverde & Associates PC
Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court.
No one is above the law. If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341.
Contact:
Juan Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4740
New York, NY 10118
United States of America
[email protected]
Tel: (212) 971-1341
Attorney Advertising. (C) 2026 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.
SAN FRANCISCO, June 15, 2026 (GLOBE NEWSWIRE) -- National shareholder rights firm Hagens Berman has launched an investigation into Hub Group, Inc. (NASDAQ: HUBG) amid a worsening series of accounting failures, disclosures of material misstatements, and emerging signs of a potential SEC investigation, according to analysts.
If you suffered significant losses investing in Hub Group, Inc. (HUBG) stock, click this link to submit your transaction details.
Visit: www.hbsslaw.com/investor-fraud/hubg
Contact the Firm Now: [email protected]
844-916-0895
New Developments: Mounting Risk and Executive Turnover:
As of June 2026, the situation at Hub Group has deteriorated significantly, raising urgent questions for shareholders:
Possible Undisclosed SEC Investigation: Analysts at Disclosure Insight recently identified an early signal of a potential SEC investigation into Hub Group. While not yet confirmed as an ongoing enforcement action, according to Disclosure Insight, the company’s recent history of undisclosed SEC activity—including a separate, previously undisclosed investigation that concluded on February 9, 2026—suggests a heightened risk profile.Abrupt Executive Departures: On May 27, 2026, the company saw the sudden, simultaneous departures of its Chief Financial Officer (CFO) and Chief Operating Officer (COO).Delisting Risk: The company has been issued a delisting notice by NASDAQ, further adding to the instability surrounding the firm’s public standing. Accounting Allegations and Internal Control Failures
The current turmoil follows a series of disclosures beginning in February 2026, when Hub Group admitted that its financial statements for the first nine months of 2025 were materially misstated due to a $77 million understatement of purchased transportation costs and accounts payable.
Subsequent filings have revealed that these accounting issues are far more pervasive than initially disclosed:
Expanded Non-Reliance: In May 2026, the company admitted that its audited financial statements for both 2023 and 2024 were also materially misstated and should no longer be relied upon.Systemic Internal Control Issues: The company has acknowledged that it did not maintain effective disclosure controls and procedures, or internal control over financial reporting, for the fiscal years 2023, 2024, and 2025.Unsupported Transactions: A review directed by the Audit Committee identified transactions that were "prematurely or incorrectly recognized or not adequately supported," leaving investors in the dark regarding the true state of the company’s finances. Investor Alert:
Hagens Berman is investigating whether Hub Group and its management misled investors regarding the company's internal accounting controls and financial health. Investors who have suffered significant losses are encouraged to submit their information to the firm.
“Now that Hub Group has almost cleaned out its C-suite following an accounting error that reaches all the way back to 2023, the core focus of our investigation is whether these expenses were intentionally or recklessly understated to artificially inflate operating margins,” said Reed Kathrein, the Hagens Berman partner leading the firm’s investigation.
If you invested in Hub Group and have substantial losses, or have knowledge that may assist the firm’s investigation, submit your losses now »
If you’d like more information and answers to other frequently asked questions about the firm’s Hub Group investigation, read more »
Whistleblowers: Persons with non-public information regarding Hub Group should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Reed Kathrein at 844-916-0895 or email [email protected].
About Hagens Berman
Hagens Berman is a global plaintiffs’ rights complex litigation firm focusing on corporate accountability. The firm is home to a robust practice and represents investors as well as whistleblowers, workers, consumers and others in cases achieving real results for those harmed by corporate negligence and other wrongdoings. Hagens Berman’s team has secured more than $2.9 billion in this area of law. More about the firm and its successes can be found at hbsslaw.com. Follow the firm for updates and news at @ClassActionLaw.
, /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving The Ensign Group, Inc. (NASDAQ: ENSG).
If you have information that could assist in the Ensign investigation or if you are an Ensign investor who suffered a loss and would like to learn more, you can provide your information here:
You can also contact attorneys Ken Dolitsky or Michael Albert of Robbins Geller by calling 800/851-7783 or via e-mail at [email protected].
THE COMPANY: Ensign provides skilled nursing, senior living, and rehabilitative services.
THE REVELATION: On June 11, 2026, Muddy Waters Research published a report titled "Ensign: Deceiving the Government at Estimated ~20% of Facilities: Multi-Billion Dollar Potential Liability, Margins and Acquisitions that Cannot be Sustained Without Significant Ongoing Misconduct." On this news, the price of Ensign stock fell.
ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder rights litigation. Our Firm ranked #1 on the most recent ISS Securities Class Action Services Top 50 Report, recovering more than $916 million for investors in 2025. This marks our fourth #1 ranking in the past five years. And in those five years alone, Robbins Geller recovered $8.4 billion for investors – $3.4 billion more than any other law firm. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Contact:
Robbins Geller Rudman & Dowd LLP
Ken Dolitsky
Michael Albert
655 W. Broadway, Suite 1900, San Diego, CA 92101
800/851-7783
[email protected]
June 15, 2026 16:05 ET | Source: The Ensign Group, Inc.
SAN JUAN CAPISTRANO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG) (“Ensign” or the “Company”), the parent company of the EnsignTM group of companies, which invest in and provide skilled nursing and senior living services, physical, occupational and speech therapies, other rehabilitative and healthcare services, and real estate, announced today that its Board of Directors has approved a $60 million increase to the Company’s previously approved $40 million stock repurchase program, bringing the Company’s total authorized repurchase capacity to $100 million. Repurchases under the expanded program are expected to commence in the near term.
"Ensign’s strong financial performance reflects the benefits of our proven business model built on clinical excellence, local leadership and a culture focused on providing compassionate, high-quality care for our residents," said Barry Port, Ensign's Chairman and Chief Executive Officer. “We believe that foundation, together with the continued trust and support from our communities and the strong demand we see across our markets, positions us well for continued long‑term success. The increased stock repurchase authorization underscores our confidence in the strength, integrity and upside potential of our company, as well as our ongoing commitment to disciplined capital allocation.”
Under the stock repurchase program, the Company is authorized to repurchase its issued and outstanding common shares from time to time in open-market and privately negotiated transactions and block trades in accordance with federal securities laws, including Rule 10b-18 and Rule 10b5-1. The timing and actual number of shares repurchased by the Company under this program will depend on a variety of factors, including price, trading volume, general market conditions, and other corporate considerations. The Company has no obligation to repurchase any particular dollar amount or number of shares under the stock repurchase program, and the program may be suspended, discontinued or modified at any time, without prior notice and subject to legal and regulatory requirements.
This press release contains “forward-looking” statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These statements are based on management’s current expectations, assumptions and beliefs about its business, financial performance, operating results, the industry in which it operates and other future events. Forward-looking statements can often be identified by words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "could," "potential," "continue," "ongoing," similar expressions, and variations or negatives of these words. These forward-looking statements include, but are not limited to, statements regarding the amount, timing and execution of the stock repurchase program, growth prospects, and future operating and financial performance. They are not guarantees of future results and are subject to risks, uncertainties and assumptions that could cause actual results to materially and adversely differ from those expressed in any forward-looking statement.
These risks and uncertainties relate to the Company’s business, its industry and its common stock and include: reduced prices and reimbursement rates for its services; its ability to acquire, develop, manage or improve operations, its ability to manage its increasing borrowing costs as it incurs additional indebtedness to fund the acquisition and development of operations; its ability to access capital on a cost-effective basis to continue to successfully implement its growth strategy; its operating margins and profitability could suffer if it is unable to grow and manage effectively its increasing number of operations; competition from other companies in the acquisition, development and operation of facilities; its ability to defend claims and lawsuits, including professional liability claims alleging that our services resulted in personal injury, and other regulatory-related claims; and the application of existing or proposed government regulations, or the adoption of new laws and regulations, that could limit its business operations, require it to incur significant expenditures or limit its ability to relocate its operations if necessary. Additionally, our business and operations continue to be impacted by the unprecedented nature of the changes in the regulations and environment, as such, we are unable to predict the full extent and duration of the financial impact of these changes on our business, financial condition and results of operations. Therefore, our actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors. Readers should not place undue reliance on any forward-looking statements and are encouraged to review the Company’s periodic filings with the Securities and Exchange Commission, including its Form 10-Q and 10-K, for a more complete discussion of the risks and other factors that could affect Ensign’s business, prospects and any forward-looking statements. Except as required by the federal securities laws, Ensign does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changing circumstances or any other reason after the date of this press release.
About EnsignTM
The Ensign Group, Inc.'s independent operating subsidiaries provide a broad spectrum of skilled nursing and senior living services, physical, occupational and speech therapies and other rehabilitative and healthcare services at 396 healthcare facilities in Alabama, Alaska, Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, Oregon, South Carolina, Tennessee, Texas, Utah, Washington and Wisconsin. More information about Ensign is available at http://www.ensigngroup.net.
Applovin Corp (NASDAQ:APP) is enjoying broader market tailwinds, last seen up 4.9% at $521.05. The stock has had a volatile year, recently falling from an early-June multi-month peak, but a bullish signal now flashing could mean even more short-term gains.
According to Schaeffer's Senior Quantitative Analyst Rocky White, APP is trading within 0.75 times the 50-day moving average's 20-day average true range (ATR), after spending at least 80% of the previous two weeks and 80% of the prior 42 trading sessions above that trendline.
This setup has appeared six times during the last decade, after which the stock was higher one month later 83% of the time, averaging an impressive 6.4% gain. A comparable rally from current levels would put Applovin stock at $554.39.
Furthermore, the 12.83 million shares sold short account for 5.14% of KR's available float, and it would take short sellers roughly three days to buy back their bearish bets at the stock's average pace of trading.
Options are affordably priced at the moment, per Applovin stock's Schaeffer’s Volatility Index (SVI) of 67% that stands in the 22nd percentile of its annual range. The stock tends to outperform these volatility expectations, too, according to its Schaeffer's Volatility Scorecard (SVS), which comes in at 80 out of 100.
New York, New York and New Orleans, Louisiana--(Newsfile Corp. - June 15, 2026) - Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in PicS N.V. ("PicS" or the "Company") (NASDAQ: PICS) of a class action securities lawsuit.
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of investors of PicS who were adversely affected if they purchased the Company's Class A common stock in and/or traceable to its January 30, 2026 initial public offering (the "IPO"). This action is pending in the United States District Court for the Southern District of New York.
Cannot view this video? Visit:
https://www.youtube.com/watch?v=FQIEqld_vCU
Follow the link below to get more information and be contacted by a member of our team:
https://www.ksfcounsel.com/cases/nasdaqgs-pics/
PicS investors should contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email ([email protected]), or visit https://www.ksfcounsel.com/cases/nyse-ses/?prs=nf to learn more.
CASE DETAILS: According to the Complaint, PicS and certain of its executives are charged with failing to disclose material information in the Offering Documents, violating federal securities laws. The alleged false and misleading statements and omissions include, but are not limited to, that: (i) in December 2025, the Company determined that its credit assessment procedures were deficient and required enhancement; (ii) following implementation of revised procedures, the Company reclassified approximately R$590 million of exposures from Stage 2 to Stage 3, resulting in an incremental ECL charge of R$88 million for the quarter ended December 31, 2025; (iii) the Company experienced an undisclosed Stage 3 formation rate exceeding 7% in the fourth quarter of 2025, materially departing from the historical trends disclosed in the offering documents; (iv) the offering documents materially overstated the effectiveness of PicS N.V.'s credit models, user data, and underwriting and risk-monitoring capabilities; and (v) prior to the IPO, PicS N.V.'s expansion into riskier business lines had led to deteriorating credit quality, increased default and impairment risk, and adverse financial and operational trends that were expected to continue worsening and materially impact the Company's business and financial results.
The case is FirstFire Global Opportunities Fund, LLC v. PicS N.V., No. 26-cv-04793.
WHAT TO DO? If you invested in PicS and suffered a loss during the relevant time frame, you have until August 4, 2026 to request that the Court appoint you as lead plaintiff; however, your ability to share in any recovery does not require that you serve as a lead plaintiff.
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, and a representative office in Luxembourg.
TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services
To learn more about KSF, you may visit www.ksfcounsel.com.
BENSALEM, Pa., June 15, 2026 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the deadlines listed below to file a lead plaintiff motion.
Investors suffering losses on their investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in these class actions at (215) 638-4847 or by email to [email protected].
Phreesia Inc. (NYSE: PHR)
Class Period: May 8, 2025 – March 30, 2026
Lead Plaintiff Deadline: July 13, 2026
The complaint alleges that throughout the Class Period the defendants created the false impression that they possessed reliable information pertaining to the Company’s long-term growth outlook through expansion of its key revenue platforms and remained confident in its revenue growth projections for fiscal year 2027, while also minimizing risks from slowing growth in its Network Solutions segment. In truth, Phreesia’s portrayal of its pharmaceutical marketing commitments as a durable growth driver of its Network Solutions segment was uncertain thereby putting the 2027 revenue target at risk.
Sportradar Group AG (NASDAQ: SRAD)
Class Period: November 7, 2024 – April 21, 2026
Lead Plaintiff Deadline: July 17, 2026
The complaint alleges that throughout the Class Period the defendants made false and/or misleading statements and/or failed to disclose that: (1) Sportradar intentionally worked with black-market gambling operators to increase its revenues, despite its assurances of strict legal and regulatory compliance and claims that ethics and integrity were crucial for Sportradar’s operations; (2) the Company’s KYC and compliance processes were not as robust as Defendants’ had claimed; and (3) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
Commvault Systems Inc. (NASDAQ: CVLT)
Class Period: April 29, 2025 – January 26, 2026
Lead Plaintiff Deadline: July 17, 2026
The complaint alleges that throughout the Class Period the defendants made false and/or misleading statements and/or failed to disclose that: (1) Commvault knew or recklessly disregarded the impact that different types of sales would have on its ARR growth; (2) the variation in net ARR growth is strongly based on the type of sale Commvault is making, thus, the Company’s projected net new ARR should not have been determined without properly factoring in sale type; and (3) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
Veritone, Inc. (NASDAQ: VERI)
Class Period: October 14, 2025 – April 14, 2026
Lead Plaintiff Deadline: July 20, 2026
The complaint alleges that throughout the Class Period the defendants made false and/or misleading statements and/or failed to disclose: (1) that the Company inaccurately recorded and/or misclassified certain revenue and costs; (2) that, as a result, the Company overstated its revenue, assets, accounts receivable, royalties and other comprehensive income; (3) that Veritone maintained deficient internal controls over accounting and financial reporting; (4) that, as a result of the foregoing, the Company would be forced to restate certain of its financial statements, and (5) that, as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
To be a member of these class actions, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about these class actions, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847 or by email to [email protected], or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contacts
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847 [email protected]
www.howardsmithlaw.com
NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP alerts investors in Commvault Systems, Inc. (NASDAQ: CVLT) that a securities class action has been filed on behalf of shareholders who purchased securities between April 29, 2025 and January 26, 2026. Find out if you qualify to recover losses from the CVLT analyst downgrade fallout. You may also contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500.
CVLT shares collapsed 31%, losing $40.23 per share in a single trading session on January 27, 2026, after third quarter fiscal 2026 results revealed net new ARR of $39 million versus the $45 million target. Multiple sell-side firms immediately cut their price targets and downgraded their ratings.
Initial Analyst Optimism Built on Company Projections
Throughout the Class Period, Wall Street coverage of Commvault reflected confidence in the Company's ARR growth trajectory. That confidence, the lawsuit contends, was built on projections that failed to account for how SaaS deal mix would dilute reported ARR. Analysts modeled forward estimates using the $40 million and later $45 million quarterly net new ARR baselines management provided on successive earnings calls.
The Downgrades Begin: January 27, 2026
The corrective disclosure triggered swift reassessment across the analyst community:
CFRA downgraded Commvault from Buy to Hold and slashed its price target from $172 to $101, a 41% reductionMizuho lowered its target from $180 to $140, noting the "underwhelming F3Q" and attributing the shortfall to "a growing SaaS net new ARR mix shift" with "much lower ASPs"DA Davidson cut its target from $185 to $135, stating that management's explanations for the ARR miss "leave many with questions" and that the reasoning did "not seem to have been enough for investors"
Execution Concerns Replace Confidence on Wall Street
DA Davidson's analysis was particularly pointed. The firm observed that for management's SaaS-mix explanation to hold, one would need to believe that approximately $1.6 million in SaaS upside somehow prevented representatives from closing term-license deals with entirely different customers. The report noted that Commvault had previously demonstrated both SaaS and term-license upside in the same quarter, undermining the argument that one came at the expense of the other. As the filing states, these analyst reactions reflect the market's conclusion that the guidance provided during the Class Period was materially flawed.
Why Analyst Shifts Matter for CVLT Investors
When sell-side consensus is built on company-provided projections that allegedly omit material variables, the resulting correction can be severe. The aggregate target price reduction across covering firms exceeded $40 per share on average, as alleged in the action. Investors who purchased CVLT stock during the Class Period at prices supported by analyst models that relied on the Company's guidance may have overpaid significantly.
"When analyst expectations are built on incomplete or misleading company disclosures, the resulting corrections can cause significant investor harm. The breadth of the downgrades following Commvault's January disclosure underscores how widely the prior guidance was relied upon." -- Joseph E. Levi, Esq.
Speak with an attorney about recovering your CVLT investment losses or call (212) 363-7500.
ABOUT LEVI & KORSINSKY, LLP -- Over the past 20 years, Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders. The firm has extensive expertise in complex securities litigation and a team of over 70 employees. For seven consecutive years, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report. The last day to move for lead plaintiff is July 17, 2026.
Frequently Asked Questions About the CVLT Lawsuit
Q: How much did CVLT stock drop? A: Shares fell approximately 31% -- a decline of $40.23 per share -- after the company disclosed that third quarter fiscal 2026 net new ARR came in at $39 million versus the $45 million projection. Investors who purchased shares during the class period at artificially inflated prices may be entitled to compensation.
Q: What specific misstatements does the CVLT lawsuit allege? A: The complaint alleges Commvault made materially false or misleading statements regarding its ARR growth trajectory and guidance for fiscal year 2026, failing to properly account for how SaaS deal mix and longer-duration term licenses would dilute reported ARR. When the true state was revealed, the stock price declined sharply.
Q: What do CVLT investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at [email protected] or (212) 363-7500. No immediate action is required to remain eligible as a class member.
Q: What is a lead plaintiff and why does it matter? A: A lead plaintiff is the investor appointed by the court to represent the entire class. Lead plaintiffs are typically investors with the largest documented losses. Being appointed does not increase individual recovery but gives direct oversight of how the case is run.
Q: What if I already sold my CVLT shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold them. Investors who bought during the class period and sold at a loss may still participate.
Q: What does it cost me to participate? A: Nothing. Securities class actions are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.
Q: Can I join a different law firm's lawsuit instead? A: Multiple firms often file competing complaints. The court consolidates and appoints a single lead counsel. Contacting Levi & Korsinsky before July 17, 2026 ensures your losses are considered.
Ameriprise Financial has underperformed, but I see AI-driven fears over cash sweep revenue as overdone, given AMP's diversified model. AMP's Q1 earnings were strong, with $11.26 EPS, 9% revenue growth, and 150bps margin expansion, aided by robust AUM growth and advisor productivity. I expect 2026 EPS of $44–$45.50, up from prior estimates, as market gains and stable rates boost advisory and cash revenue.
Key Takeaways BE shares have soared 69% in three months, outpacing its industry, sector and the S&P 500.Bloom Energy is gaining from AI data-center demand and distributed energy adoption amid grid limits.BE's 2026 and 2027 revenue and earnings estimates signal sharp year-over-year growth. Bloom Energy Corporation (BE - Free Report) is currently trading at a premium valuation. Its forward 12-month price-to-sales (P/S) ratio of 15.64X stands higher than the industry’s 4.99X and the median of 2.3X over the last three years.
Bloom Energy is a global leader in onsite power generation, gaining from increasing demand for clean energy from AI-driven data centers, as well as from customers increasingly adopting distributed energy solutions to bypass transmission and distribution constraints.
Image Source: Zacks Investment Research
BE is expensive compared to other industry players like Talen Energy Corporation (TLN - Free Report) and Plug Power Inc. (PLUG - Free Report) .
BE: An OutperformerShares of BE have surged 69.4% in the past three months against the Zacks Alternative Energy - Other industry’s decline of 2%. The company has also outperformed the Zacks Oil & Energy sector, which has lost 0.8%, and the S&P 500, which has risen 11.1%, in the same time frame.
Image Source: Zacks Investment Research
Shares of other industry players like Talen Energy and Plug Power have gained 13.6% and 23.2%, respectively, in the past three months.
The Case for Bloom EnergyBloom Energy’s strategy centers on scaling its onsite power platform to address a world where electricity availability, deployment speed and energy costs are increasingly critical constraints. The company is focused on capitalizing on four major structural trends transforming global energy demand — the rapid growth of AI-driven infrastructure, ongoing grid capacity limitations, the need for greater power reliability and affordability, and government policies that emphasize energy independence and U.S. competitiveness in the digital economy.
As electricity demand continues to outpace supply, weaknesses in transmission and distribution networks are becoming more pronounced. Bloom Energy’s Energy Server platform is designed to address these challenges by operating alongside the grid and connecting directly to a customer’s primary electrical system, reducing inefficiencies associated with centralized power generation. Its modular design allows customers to scale capacity seamlessly, from a few hundred kilowatts to several hundred megawatts.
The Energy Server platform delivers efficient, reliable and cleaner power solutions for commercial and utility customers. Built on Bloom’s proprietary solid oxide technology, the system generates electricity through an electrochemical process rather than combustion. This positions the company to benefit from rising demand for dependable energy solutions, driven by AI data centers, cryptocurrency mining operations and the reshoring of manufacturing activities in the United States.
Bloom Energy continues to invest in research and development to enhance system efficiency, lower production costs and improve profitability. The company also stands to gain from government incentives that support clean energy deployment and innovation.
Over the long term, Bloom Energy aims to establish solid oxide fuel cell technology as the preferred architecture for onsite power generation across data centers, advanced manufacturing facilities, critical infrastructure, and other energy-intensive industries worldwide. As power demand accelerates and organizations seek alternatives to traditional grid-based electricity, BE is positioning its fuel cell platform as a key solution for the next generation of high-power applications.
Optimistic Growth Estimate for BEThe Zacks Consensus Estimate for 2026 and 2027 revenues implies 80.3% and 66.7% year-over-year increases, respectively.
The consensus estimate for 2026 and 2027 earnings implies 151.3% and 108.5% year-over-year increases, respectively. The company has a Growth Score of A.
Image Source: Zacks Investment Research
However, the Zacks Consensus Estimate for Bloom Energy’s 2026 and 2027 earnings witnessed no movement in the last 30 days.
BE Stock Returns Better Than Its IndustryThe return on equity (“ROE”) measures how well a company is utilizing its shareholders’ funds to generate profits. ROE compares net income with shareholders' equity.
ROE of Bloom Energy was 43.41% compared with the industry average of 7.11%.
Parting Thoughts on BEBloom Energy continues to demonstrate resilient performance, supported by rising demand for clean energy and its ability to provide rapid and dependable power solutions. Demand for the company’s offerings is expected to grow further as it delivers customized clean energy solutions directly to customers, reducing reliance on traditional transmission and distribution infrastructure.
Bloom Energy appears to be an attractive investment option, backed by improving earnings estimates, strong stock price momentum and a return on equity that surpasses industry peers.
Thus, despite premium valuation at the current levels, we recommend investors add this Zacks Rank #1 (Strong Buy) to their portfolios.
You can see the complete list of today’s Zacks #1 Rank stocks here.
Celsius Holdings stock is under selling pressure. What’s driving CELH stock lower? What Is Driving CELH Stock Lower Today?The market pivoted sharply today following news that the U.S. and Iran signed a peace agreement to reopen the Strait of Hormuz. The deal sent crude oil prices tumbling by 5%, significantly easing global inflation fears. This development sparked a powerful relief rally, sending the Nasdaq-100 up over 3%.
As a prominent growth name within the consumer staples sector, Celsius is caught in the crosshairs of this capital flight. While lower oil prices will ultimately benefit Celsius by reducing its long-term shipping, logistics and distribution costs, Monday afternoon’s price action appears driven by macro fund flows.
Investors are prioritizing tech upside over consumer staples holdings, pulling CELH shares down despite the company’s solid independent outlook.
CELH Technical Analysis: Key Levels To WatchCELH is still trading below every major moving average, which keeps the bigger-picture bias tilted bearish: it's about 3.8% below the 20-day SMA ($29.72) and about 37.2% below the 200-day SMA ($45.54). The 20-day SMA remains below the 50-day SMA, and the death cross that formed in March (50-day dropping under the 200-day) reinforces that sellers have controlled the intermediate trend.
RSI is the cleaner momentum read right now, sitting at 45.12—neutral, but slightly on the soft side, which fits a market where rebounds are struggling to turn into sustained uptrends. RSI is basically a "stretch gauge," and a mid-40s reading suggests neither panic selling nor strong accumulation is dominating.
From a structure standpoint, the stock is hovering just above its 52-week low zone (low at $27.47), after a recent swing low in June and a swing high back in April. That backdrop matters because failed bounces near the lows often turn into "support tests" where buyers need to show up quickly to avoid a breakdown.
Key Resistance: $33.50 — a nearby ceiling where rebounds can stall, sitting in the same general area as the stock's lower moving-average band (around the low $30s). Key Support: $27.50 — a near-term floor just above the 52-week low area, where a break would put the stock back into fresh-low territory. What Is Celsius Holdings and Its Market Position?Celsius Holdings operates in the energy drink subsegment of the global nonalcoholic beverage market, with 95% of revenue concentrated in North America. It owns three energy drink brands: Celsius, Alani Nu and Rockstar Energy.
The company leans on product innovation and marketing while outsourcing manufacturing and packaging to third-party co-packers, and it uses PepsiCo for distribution. Celsius also issued convertible preferred shares following PepsiCo's investments in 2022 and 2025, which left PepsiCo with an 11% stake, an important strategic tie as the brand competes for shelf space and mindshare in a crowded category.
Celsius Holdings Benzinga Edge Rankings OverviewBelow is the Benzinga Edge scorecard for Celsius Holdings, highlighting its strengths and weaknesses compared to the broader market:
The Verdict: Celsius Holdings’s Benzinga Edge signal reveals weak readings across momentum, growth, value, and quality, which matches a chart that's still trying to stabilize near its lows. For longer-term bulls, the cleaner setup usually comes after momentum improves and price starts reclaiming the low-$30s resistance zone rather than repeatedly failing below it.
CELH Stock Price Action Update for MondayCELH Stock Price Activity: Celsius Holdings shares were down 1.23% at $28.83 at the time of publication on Monday, according to Benzinga Pro data.
Image: Shutterstock
Market News and Data brought to you by Benzinga APIs
A US-Iran deal that could reopen the Strait of Hormuz led to mixed fertilizer stock reactions. (Scott Olson/Getty Images)
Fertilizer stocks had a mixed reaction after the U.S. and Iran reached a preliminary deal that could ease the supply shock that lifted fertilizer prices earlier this year. The deal is good news for fertilizer buyers, but bad news for producers.
, /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2025 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating Payoneer Global Inc. (NASDAQ: PAYO) related to its sale to Nuvei. Under the terms of the proposed transaction, Payoneer shareholders are expected to receive $7.40 per share in cash. Is it a fair deal?
Click here for more info https://monteverdelaw.com/case/payoneer-global-inc/. It is free and there is no cost or obligation to you.
NOT ALL LAW FIRMS ARE EQUAL. Before you hire a law firm, you should talk to a lawyer and ask:
Do you file class actions and go to Court? When was the last time you recovered money for shareholders? What cases did you recover money in and how much? About Monteverde & Associates PC
Our firm litigates and has recovered money for shareholders…and we do it from our offices in the Empire State Building. We are a national class action securities firm with a successful track record in trial and appellate courts, including the U.S. Supreme Court.
No one is above the law. If you own common stock in the above listed company and have concerns or wish to obtain additional information free of charge, please visit our website or contact Juan Monteverde, Esq. either via e-mail at [email protected] or by telephone at (212) 971-1341.
Contact:
Juan Monteverde, Esq.
MONTEVERDE & ASSOCIATES PC
The Empire State Building
350 Fifth Ave. Suite 4740
New York, NY 10118
United States of America
[email protected]
Tel: (212) 971-1341
Attorney Advertising. (C) 2026 Monteverde & Associates PC. The law firm responsible for this advertisement is Monteverde & Associates PC (www.monteverdelaw.com). Prior results do not guarantee a similar outcome with respect to any future matter.
Key Takeaways MAC gained 57.4% in 12 months, backed by leasing progress and 94.5% go-forward occupancy.MAC trades at 16.39X forward FFO; a $27 target implies limited upside after the rally.MAC beat Q1 FFO estimates, but leverage remains high and dividend growth appears constrained. The Macerich Company (MAC - Free Report) has rewarded investors with a sharp rally, but the buying case is no longer straightforward. The stock’s operating story has improved, while valuation and leverage leave less room for error.
For investors, MAC looks more like a selective hold than a clear bargain after its run. The question is whether future net operating income growth can justify further upside.
MAC Shows Strong Momentum but a Neutral CaseMAC shares are up 57.4% over the trailing 12-month period, outpacing the Zacks sub-industry’s 21.1% gain and the Zacks Finance sector’s 14.7% rise. That performance reflects better investor confidence in high-quality malls.
Image Source: Zacks Investment Research
The optimism is supported by leasing progress. Roughly 90% of go-forward net operating income comes from Class A properties, while go-forward portfolio occupancy was 94.5% as of March 31, 2026.
Simon Property Group (SPG - Free Report) is a relevant peer because it owns premier shopping, dining, entertainment and mixed-use destinations. Tanger Inc. (SKT - Free Report) also provides useful retail real estate context as an owner and operator of outlet and open-air shopping destinations.
MAC Valuation Looks Fair, Not CheapMAC trades at 16.39X forward 12-month funds from operations. That is below the Zacks sub-industry’s 17.16X and the S&P 500’s 21.41X, but slightly above the Zacks sector’s 16.18X.
Image Source: Zacks Investment Research
The $27 price target, based on a 17.39X target multiple, points to limited incremental upside rather than a deep-value setup. MAC is not obviously expensive, but the rally has already priced in part of the recovery.
MAC Earnings Support Is Improving SlowlyFirst-quarter 2026 funds from operations, as adjusted, came in at 34 cents per share, matching the year-ago quarter and beating the Zacks Consensus Estimate by 9.68%. Revenues of $241.54 million declined 3.1% year over year but topped the consensus mark by 1.2%.
Estimate trends have improved only modestly. The current-year funds from operations estimate moved 1.2% higher over the past four weeks.
Management also lifted its 2028 target funds from operations range to $1.80-$2.00 per share. Still, annual estimates of $1.46 for 2026 and $1.56 for 2027 suggest measured progress rather than rapid earnings acceleration.
MAC Still Carries Leverage and Dividend LimitsLeverage remains the main counterweight. Net debt to adjusted EBITDA was 7.76X as of March 31, 2026, while pro forma leverage was about 7.26X after the Annapolis Mall acquisition and follow-on equity issuance.
Property-level issues also matter. The $76.5 million pro rata loan at Twenty Ninth Street was in default as of Feb. 6, 2026, with the joint venture still negotiating terms with the lender.
The dividend is another restraint. MAC paid 17 cents per share in the first quarter and announced another 17-cent quarterly dividend payable in June 2026, leaving limited near-term dividend growth while redevelopment and balance-sheet repair remain priorities.
What MAC’s Ratings Say About TimingMAC’s operating recovery is real, but the stock looks closer to fairly valued than mispriced. Investors buying now are paying for continued leasing execution, higher occupancy and net operating income gains through 2028.
MAC currently carries a Zacks Rank #3 (Hold). That rank supports a wait-and-see approach rather than an aggressive buying stance. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Style Scores point in the same direction. MAC has a Value Score of C, Growth Score of D, Momentum Score of D and VGM Score of D. The Value Score suggests valuation is not a major red flag, but the weak Growth, Momentum and VGM scores favor selectivity for investors seeking stronger near-term ranking support.
Note: Anything related to earnings presented in this write-up represents funds from operations (FFO) — a widely used metric to gauge the performance of REITs.
Organizations that pair mature technology infrastructure with a fundamentals-first AI investment strategy outperform laggards by 31% on composite outcomes—and could unlock trillions in unrealized value across the G2000
, /PRNewswire/ -- Cognizant (NASDAQ: CTSH) today released new research showing that AI's real-world results depend less on the technology itself than on the maturity of a company's tech infrastructure and where it directs its investment. The companies getting this right are generating financial returns measurable in the billions.
The study, "Closing the AI Execution Gap: A $2 Billion Business Boost," surveyed 1,100 senior business leaders at Global 2000 companies and 100 startups across 10 industries. Its central finding is stark: two-thirds of leaders have yet to demonstrate measurable business productivity gains from AI, and one in four have already paused or abandoned AI deployments—with an estimated average of $2 billion in unrealized cost savings and revenue opportunity.
The research identifies a clear set of behaviors that separates the top performers from the rest.
31% — The performance gap between the highest- and lowest-performing AI segments on composite outcomes.
$1B–$2B — Estimated annual returns available to a typical G2000 company that moves from the weakest to the strongest performing segment.
$4.7T — Total unrealized annual value across the G2000 when worker productivity, business productivity, revenue and cost reduction are included.
60% — How much more likely organizations with immature infrastructure and broad AI investment are to abandon a deployment versus those with the same infrastructure who invest in AI fundamentals first.
27% — Productivity advantage held by organizations with strong data foundations versus those still working to improve theirs.
"The evidence in this research could not be more direct: companies that build on a mature technology foundation and invest in AI fundamentals first are already generating billions in returns that their competitors are leaving on the table," said Cognizant CEO Ravi Kumar S. "This is the AI Builder dividend and it is real, it is quantifiable, and it is widening. Two-thirds of organizations have yet to move the needle on business productivity from AI. That is not a capability gap in technology. That is an execution gap. Cognizant exists precisely to close it. We help companies do the work that unlocks AI value: strengthening compute infrastructure, building data foundations that AI can trust, and deploying the focused investment strategies that turn AI's potential into verifiable, compounding returns."
The research shows organizations can continue to improve their AI outcomes through building technical and data foundations, focusing investment strategies, and leveraging strong external partnerships where needed:
Organizations with focused AI investment strategies outperform their peers regardless of maturity level—even lower-maturity companies with a focused approach achieve an 11.4% composite outcome score, versus 9.7% for same-maturity peers investing broadly Compute and data foundations are the most consequential infrastructure factors; just 19.9% of organizations rate their on-premises compute as excellent—and companies with excellent cloud compute outperform those with adequate ratings by 4.8 percentage points in worker productivity gains Data gaps are pervasive: 64.5% of organizations have at least one of five key data dimensions rated adequate or below; organizations with strong data foundations report nearly 27% higher productivity gains and are 20%+ less likely to abandon AI initiatives Infrastructure quality has a compounding effect on outcomes—organizations with all 10 infrastructure dimensions rated good or excellent achieve 15.6% average productivity gains; that drops to 14.1% with just one adequate dimension, and to 12.5% when any dimension needs improvement High-performing organizations are significantly more likely to work with external partners: 72–76% of focused-strategy companies engage outside expertise, compared to 54–60% of broad-investment peers ABOUT COGNIZANT
Cognizant (Nasdaq: CTSH) is an AI Builder and technology services provider, bridging the gap between AI investment and enterprise value by building full-stack AI solutions for our clients. Our deep industry, process and engineering expertise enables us to build an organization's unique context into technology systems that amplify human potential, drive tangible outcomes and keep global enterprises ahead in a fast-changing world. See how at cognizant.ai or @cognizant.
NORTH ANDOVER, Mass.--(BUSINESS WIRE)--Watts Water Technologies, Inc. (NYSE: WTS) – through its subsidiaries, one of the world’s leading manufacturers and providers of plumbing, heating and water quality products and solutions – today announced the release of its 2025 Sustainability report, which highlights the Company’s dedication to environmental, social and governance practices and continued commitment to creating high-performance solutions that promote sustainability and efficiency.
“Since setting our first-generation environmental goals in 2018, we have significantly reduced our water use, emissions and hazardous waste while continuing to grow as a company. That progress gives us confidence as we pursue our next generation of goals and continue challenging ourselves to make an even greater impact in the years ahead,” said Robert J. Pagano, Jr., CEO, President and Chairperson of the Board. “Reflecting on more than a decade of sustainability work, it is rewarding to see how far we have come and the measurable progress our teams have made across the business.”
Key accomplishments highlighted in the report include:
Advanced Watts’ second generation of environmental goals, adopted in 2024, by recommitting to 3% annual intensity reductions and targeting a reduction of 10,000 metric tons of CO2 equivalent (MTCO2e) in primary emissions by 2034 Reduced water intensity by 64% and absolute water consumption by 44% between 2018 and 2025, resulting in a reduction of nearly 100 million liters of water Reduced GHG intensity by 63% and absolute GHG emissions by 43% between 2018 and 2025, resulting in a reduction of nearly 15,000 MTCO2e in Scope 1 & 2 market-based emissions Reduced hazardous waste intensity by 57% and absolute hazardous waste generation by 34% between 2018 and 2025, resulting in a reduction of nearly 700,000 kilograms of hazardous waste In 2025, we completed Life Cycle Assessments (LCAs) for all products in our BLÜCHER facility and began LCA modeling at five additional manufacturing facilities, building on LCAs already completed for all products produced in our largest facility in Franklin, NH By the end of 2025, we had published 28 Environmental Product Declarations (EPDs) covering 39 product types and are on track to exceed our goal of publishing 50 EPDs by 2026 In 2025, AERCO, PVI, and the LYNC brands of boilers, water heaters, and heat pumps helped customers avoid more than 115,000 MT of CO2, almost three times the Watts Scope 1 and Scope 2 emissions for 2025 Employees volunteered more than 10,000 hours as part of the Watts Cares community giving program, more than doubling the number of hours volunteered in 2024 – the program’s inaugural year Provided clean water access to vulnerable communities through the company’s ongoing partnership with Planet Water Foundation, which in 2025 benefited nearly 89,000 people in six different countries Recognized in 2025 for sustainability and workplace achievements including Newsweek World’s Greenest Companies and America’s Most Responsible Companies, TIME America’s Top Green Tech Companies and America’s Best Companies, USA Today America’s Climate Leaders, Barron’s 100 Most Sustainable Companies, Great Place to Work Greater China, Best Workplaces for Women in Greater China and Top Places to Work Massachusetts To download Watts’ 2025 Sustainability Report or learn more about the Company’s sustainability programs, visit http://www.watts.com/our-story/sustainability.
Watts Water Technologies, Inc. (NYSE: WTS) – through its subsidiaries, one of the world’s leading manufacturers and providers of plumbing, heating and water quality products and solutions – today announced the release of its 2025 Sustainability report, which highlights the Company’s dedication to environmental, social and governance practices and continued commitment to creating high-performance solutions that promote sustainability and efficiency.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615531859/en/
“Since setting our first-generation environmental goals in 2018, we have significantly reduced our water use, emissions and hazardous waste while continuing to grow as a company. That progress gives us confidence as we pursue our next generation of goals and continue challenging ourselves to make an even greater impact in the years ahead,” said Robert J. Pagano, Jr., CEO, President and Chairperson of the Board. “Reflecting on more than a decade of sustainability work, it is rewarding to see how far we have come and the measurable progress our teams have made across the business.”
Key accomplishments highlighted in the report include:
Advanced Watts’ second generation of environmental goals, adopted in 2024, by recommitting to 3% annual intensity reductions and targeting a reduction of 10,000 metric tons of CO2 equivalent (MTCO2e) in primary emissions by 2034 Reduced water intensity by 64% and absolute water consumption by 44% between 2018 and 2025, resulting in a reduction of nearly 100 million liters of water Reduced GHG intensity by 63% and absolute GHG emissions by 43% between 2018 and 2025, resulting in a reduction of nearly 15,000 MTCO2e in Scope 1 & 2 market-based emissions Reduced hazardous waste intensity by 57% and absolute hazardous waste generation by 34% between 2018 and 2025, resulting in a reduction of nearly 700,000 kilograms of hazardous waste In 2025, we completed Life Cycle Assessments (LCAs) for all products in our BLÜCHER facility and began LCA modeling at five additional manufacturing facilities, building on LCAs already completed for all products produced in our largest facility in Franklin, NH By the end of 2025, we had published 28 Environmental Product Declarations (EPDs) covering 39 product types and are on track to exceed our goal of publishing 50 EPDs by 2026 In 2025, AERCO, PVI, and the LYNC brands of boilers, water heaters, and heat pumps helped customers avoid more than 115,000 MT of CO2, almost three times the Watts Scope 1 and Scope 2 emissions for 2025 Employees volunteered more than 10,000 hours as part of the Watts Cares community giving program, more than doubling the number of hours volunteered in 2024 – the program’s inaugural year Provided clean water access to vulnerable communities through the company’s ongoing partnership with Planet Water Foundation, which in 2025 benefited nearly 89,000 people in six different countries Recognized in 2025 for sustainability and workplace achievements including Newsweek World’s Greenest Companies and America’s Most Responsible Companies, TIME America’s Top Green Tech Companies and America’s Best Companies, USA Today America’s Climate Leaders, Barron’s 100 Most Sustainable Companies, Great Place to Work Greater China, Best Workplaces for Women in Greater China and Top Places to Work Massachusetts To download Watts’ 2025 Sustainability Report or learn more about the Company’s sustainability programs, visit http://www.watts.com/our-story/sustainability.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260615531859/en/
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF continues its investigation into Humana Inc. (“Humana” or “the Company”) (NYSE: HUM).
On January 18, 2024, the Company announced its financial results for the fourth quarter and full year 2023, disclosing that its benefits expense ratio increased to approximately 91.4% for the fourth quarter of 2023 and approximately 88% for the full year 2023, resulting in 2023 adjusted EPS of only $26.09 per share, or more than $2 per share less than what the Company had predicted in November 2023. Then, on January 25, 2024, the Company further disclosed a loss for the fourth quarter of 2023 and expected that higher level of medical costs would persist for all of 2024, resulting in expected 2024 adjusted EPS of only $16 per share, a $10 per share decrease from 2023, well below analysts’ expectations of $29 per share.
Thereafter, the Company and certain of its executives were sued in a securities class action lawsuit, charging them with failing to disclose material information during the Class Period in violation of federal securities laws. Recently, the Court presiding over the case denied the Company’s motion to dismiss the case in part, allowing the case to move forward.
KSF’s investigation is focusing on whether Humana’s officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws.
If you have information that would assist KSF in its investigation, or have been a long-term holder of Humana shares and would like to discuss your legal rights, you may, without obligation or cost to you, call toll-free at 1-833-938-0905 or email KSF Managing Partner Lewis Kahn ([email protected]), or visit https://www.ksfcounsel.com/cases/nyse-hum/ to learn more.
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, New Jersey, and a representative office in Luxembourg.
TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services
To learn more about KSF, you may visit www.ksfcounsel.com.
